

EACR-AACR-SIC Special Conference 2015

Poster Sessions

	ABSTRACT NR.	ABSTRACT NR.	
SUNDAY 21 JUNE 2015			
Cancer Genomics, Epigenetics and Genome Instability I			
Identification of non-coding RNAs involved in cell cycle control F. Corrà, M. Galasso, C. Zerbinati, L. Minotti, M. Previati, C.M. Croce, S. Volinia (Italy)	100	Low-dose cisplatin-etoposide regimen (CE) for pediatric patients with diencephalic syndrome (DS): A multicenter evaluation of clinical and radiological activity M. Lucchesi, S. Farina, A. Stival, L. Facchini, S. Becciani, M. Guidi, L. Genitori, M. Massimino, M. De Martino, I. Sardi (Italy)	
Characterization of circulating miRNAs in lung cancer patients: Origin and release O. Fortunato, C. Verri, M. Boeri, U. Pastorino, G. Sozzi (Italy)	101	Overexpression of hexokinase 2 (HK2) in ovarian cancer contributes to cell migration, invasion and cancer stem-like cells regulation and correlates with poor patient survival M.K.Y. Siu, Y.X. Jiang, A.N.Y. Cheung, H.Y.S. Ngan, K.K.L. Chan (Hong Kong)	
The potential role of miR-143 targeted FHIT gene in breast cancer cells G. Cecener, G. Guney Eskiler, E. Demirdogen, U. Egeli, B. Tunca (Turkey)	102	Prognostic value of HIF1A, HIF2A and HIF3A expression in Bulgarian patients with malignant glioma G. Stancheva, T. Goranova, M. Laleva, M. Kamenova, A. Mitkova, N. Velinov, G. Poptodorov, V. Mitev, N. Gabrovsky, R. Kaneva (Bulgaria)	
MicroRNAs expression analysis in high-fat diet induced NAFLD-NASH-HCC progression: Study on C57BL/6j mice A. Tessitore, G. Ciccirelli, F. Del Vecchio, D. Verzella, M. Fischietti, D. Vecchiotti, R. Sferra, A. Vetuschii, F. Zazzeroni, E. Alesse (Italy)	103	Cell and Tumour Biology I	
Stromal contribution to the colorectal cancer transcriptome C. Isella, A. Terrasi, S.E. Bellomo, C. Petti, A. Muratore, L. Trusolino, P. Cassoni, G. Storme, A. Bertotti, E. Medico (Italy)	105	Mechanism of succinate dehydrogenase D mutations mediated paraganglioma S. Teng, Y. Chang (Taiwan)	153
An integrated multi level '-omics' approach identifies Dlk1-Dio3 locus associated with miR-506 expression in epithelial ovarian cancer. A new player in disease recurrence? P. Orsini, L. De Cecco, E. Cecchin, M.L. Carcangiu, F. Raspagliesi, D. Lo Russo, G. Toffoli, D. Mezzanzanica, S. Canevari, M. Bagnoli (Italy)	106	Study of a TOP2 inhibitor to prevent cell proliferation in ALT-type cancer cells C. Lin (Taiwan)	154
Magnetic beads-based sensor for cisplatin-modified DNA I. Blazkova, K. Smerkova, M. Vlcnovska, S. Dostalova, V. Milosavljevic, P. Kopel, T. Vaculovic, S. Krizkova, V. Adam, R. Kizek (Czech Republic)	107	IL-8 induces miR-424 expression and modulates SOCS2/STAT5 signaling pathway in oral cancer H. Peng, J.R. Hsiao, M. Hsiao, J.Y. Chang, S.L. Jin, S.G. Shiah (Taiwan)	155
Genetic characterization of pure tumor cell sub-populations from a formalin-fixed paraffin-embedded sample C. Bolognesi, G. Buson, G. Medoro, M. Barberis, H. Morreau, F. Fontana, R. Tanzi, G. Giorgini, W. Corver, N. Manaresi (Italy)	108	Mechanisms of action of 3',4',5'-trimethoxyflavonol in the inhibition of prostate cancer C. Hill, A. Rufini, L. Howells, S. Sale, K. Brown (United Kingdom)	156
A new method for discovering disease-specific miRNA-target regulatory networks E. Russo, M. Baglioni, F. Geraci, M. Rizzo, G. Rainaldi, M. Pellegrini (Italy)	110	The significance of histopathological evaluation of pancreatic fibrosis to estimate pancreas cancer progression S. Osada, S. Matsui, Y. Sasaki, K. Yoshida (Japan)	157
Reversing DNA methylation of androgen responsive genes by curcumin analogue R.N. Shaw, K.M. Jackson (USA)	112	Nonsteroidal anti-inflammatory drugs (NSAID)-induced alterations in inflammatory and metabolic stress in cancer and non-cancer cells H. Raza, A. John, J. Shafarin (U.A.E.)	158
Targeting MPS1 to kill tumor cells G. Manic, M. Jemaà, M. Castedo, R. De Maria, A. Abrieu, G. Kroemer, I. Vitale (Italy)	114	MiRNA-1469 targeting STAT5A promotes apoptosis in lung cancer cells C. Lu, C. Xu, L. Zhang, Z. Liu, L. Duan (China)	159
A novel intragenic regulatory region controls RUNX2 expression in cancer cells V. Sancisi, G. Gandolfi, M. Gugnoni, D.C. Ambrosetti, A. Ciarrocchi (Italy)	116	Role of miR-338-5p as a novel modulator of chemoresistance in esophageal cancer A. Cheung, L. Han, B. Li, S.W. Tsao, S. Law, K.W. Chan (Hong Kong)	160
STARD3: A potential therapeutic target in colorectal cancer J. De Santa, S. Palazzolo, L. Scarabel, G. Toffoli, F. Rizzolio (Italy)	117	ATM kinase expression regulates breast cancer stem-like phenotype M. Antonelli, F. Pacini, M. Sambucci, R. Brandi, I. Arisi, M. D'Onofrio, D. Barila, V. Stagni (Italy)	161
Open resource CRISPR/Cas9 genome-wide sgRNA library screening platform D. Tedesco, M. Makhanov, S. Baron, D. Suchkov, A. Chenchik (USA)	118	Inhibition of c-FLIP(L) expression by miR-708 increases the sensitivity to anticancer drug in renal cancer cells T.J. Lee, E.A. Kim, S.W. Kim, K.S. Song (South Korea)	162
Carcinogenesis I			
Does Brf1 have a role in prostate carcinogenesis? S. Slater, N. Nam, K. Campbell, J. Fleming, J. Edwards, I. Ahmad, K. Blyth, O. Sansom, C.N. Robson, H.Y. Leung (United Kingdom)	139	Stromal neuregulin-1 promotes adaptive resistance in mutant BRAF melanoma C. Capparelli, S. Rosenbaum, A. Berger, A.E. Aplin (USA)	163
Prenatal irradiation increases T-cell lymphoma risk when mice are exposed to a chemical carcinogen in early life, but not after radiation alone Y. Amasaki, Y. Shang, C. Tsuruoka, S. Tani, M. Nishimura, Y. Shimada, S. Kakinuma (Japan)	140	The anti-tumor activity of a novel STAT inhibitor OPB-51602 involves targeting mitochondrial metabolism J. Hirpara, M. Surana, K.U.M.I. Higuchi, M. Motoyama, T. Tsunoda, B. Goh, S. Pervaiz (Singapore)	164
MicroRNA profiling in E6/E7 human papillomavirus-transformed human keratinocytes and exosomes M. Chiantore, G. Mangino, M. Iuliano, M.S. Zangrillo, R. Accardi, M. Tommasino, S. Columba Cabezas, M. Federico, G. Fiorucci, G. Romeo (Italy)	141	Antiproliferative effects of a Cyclooxygenase-2 inhibitor, Etoricoxib, alone and in combination with Cholecystokinin Antagonists in human pancreatic cancer cells M. Sikka, D.R.M. Chopra (India)	165
		Simvastatin chemosensitizes spheres derived from canine mammary carcinoma cells through beta-catenin/MDR1 signaling C. Torres, P. Cruz (Chile)	166

20-23
JUNE
2015

FLORENCE
ITALY

ABSTRACT NR.

ABSTRACT NR.

Multiple anti-apoptotic BCL-2-like proteins determine antimetabolic drug-mediated cell fates <u>S. Huang</u> , R. Poon (China)	167	Hypoxia modulates the expression of aldehyde dehydrogenases in colon cancer cells with ALDH7A1 emerging as a key enzyme whose functional involvement is dependent on the tumour microenvironment <u>L. Elsaalem</u> , S. Allison, M. Sutherland, R.M. Phillips, K. Pors (United Kingdom)	188
M30 assay underestimates apoptosis in the case of inadequate amount of cytokeratin 18 in lung cancer cells <u>E. Ulukaya</u> , B. Cevatemre, M. Sarimahmut, F. Ari, A.Y. Oral, F.M. Frame (Turkey)	172	Effect of mechanical properties of tumor microenvironment on breast cancer behavior <u>M. Giussani</u> , C. De Maria, F. Montemurro, R. Orlandi, C. Gelfi, G. Vozzi, T. Triulzi, E. Tagliabue (Italy)	189
Overexpression of IGF-1Ec isoform induces aggressiveness of human breast cancer MCF-7 cells <u>P. Christopoulos</u> , E. Papageorgiou, M. Koutsilieris (Greece)	173	Inhibition of SP1-DNA-binding activity is critical for melatonin-mediated suppression of matrix metalloproteinase-9 and subsequent metastatic ability in human head and neck squamous cell carcinoma <u>C. Chou</u> , S. Yang, C. Lin (Taiwan)	190
A priori activation of apoptosis pathways for treatment of triple negative breast cancer <u>R. Pandurangi</u> , M. Tomasetti, R. Gillies (USA)	174	MiR-141 not only modulates anoikis resistance of ovarian cancer cells but also alters pre-metastatic niche for ovarian cancer cell metastatic colonization <u>D. Chan</u> , C.S. Mak, H.Y. Ngan (Hong Kong)	191
Upregulation of MiR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas <u>M. Chien</u> , S. Yang, W. Lee, P.E.N.G. Tan, C. Tang, M. Hsiao (Taiwan)	175	Docosahexaenoic acid induces colon cancer cell death through AMPKa/FOXO3A/miR-21 pathway <u>A. Fluckiger</u> , A. Dumont, A. Hichami, V. Derangère, C. Rébé, C. Thomas, F. Ghiringhelli, M. Rialland (France)	194
Dehydroandrographolide inhibits migration and invasion by inhibition of matrix metalloproteinase-2 through modulation of SP-1 in human oral cancer <u>C. Lin</u> , S. Yang, M. Hsieh (Taiwan)	176	The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes tumor invasion and metastasis <u>Y.L. Li</u> , K.T. Hua, M.Y. Wang (Taiwan)	195
Metastatic associated genes in cholangiocarcinoma <u>K. Uthaisar</u> , K. Vaeteewoottacharn, W. Seubwai, C. Talabnin, K. Sawanyawisuth, S. Okada, S. Wongkham (Thailand)	177	Smad7 knockdown-induced colon cancer cell growth inhibition is mediated by protein kinase RNA-driven eIF2a hyperphosphorylation <u>V. De Simone</u> , G. Bevivino, S. Sedda, E. Franzè, A. Colantoni, A. Ortenzi, F. Pallone, G. Monteleone (Italy)	196
Tricetin suppresses migration/invasion of human glioblastoma multiforme (GBM) cells by inhibiting matrix metalloproteinase-2 <u>Y. Liaw</u> , S. Yang, M. Chien (Taiwan)	178	A role for 6-phosphofructo-2-kinase in the epithelial-mesenchymal transition of tumor cells <u>A. Yalcin</u> , S.C. Ozcan, S.C. Guzel, T.H. Solakoglu, H. Samli, J.A. Chesney (Turkey)	197
Cantharidic acid suppresses the proliferation and induces apoptosis involving MAPKs and caspase-8/-9/-3 signals in human hepatocellular carcinoma cells <u>C. Yeh</u> , S. Yang (Taiwan)	179	Suppression of PPAR β , or DHA treatment, inhibit Nav1.5 and NHE-1 proinvasive activities <u>S. Chevalier</u> , S. Roger, R. Wannous, E. Bon, L. Gillet, L. Brisson, J. Goré, P. Bougnoux, P. Besson (France)	198
Hispolon attenuates metastasis via Akt pathways in human nasopharyngeal carcinoma cells <u>S. Lin</u> , S. Yang, K. Yeh (Taiwan)	180	Colon-derived tumor initiating cells display an altered expression and function of the pro-apoptotic kinase HIPK2 <u>G. Di Rocco</u> , V. Gatti, A. Verdina, M. Tartaglia, S. Soddu (Italy)	199
Polyphyllin G induced apoptosis and autophagy in human hepatocellular carcinoma <u>H. Chiou</u> , M. Hsieh (Taiwan)	181	Serum biomarkers identification by nanoparticle technology in Giant Cell Tumor of Bone A. Conti, L. Pazzaglia, C. Novello, I. Quattrini, S. Pollino, G. Magagnoli, L.A. Liotta, P. Picci, A. Luchini, <u>M.S. Benassi</u> (Italy)	201
Dehydroandrographolide, an iNOS inhibitor, induces autophagy in human head and neck cancer <u>S. Yang</u> , M. Hsieh, C. Lin (Taiwan)	182	Studying the contribution of putative platinum drug uptake channels as drug resistance mechanism in Brca1-mutated mammary tumor cells <u>M. Dettwiler</u> , C. Guyader, N. Gerhards, O. Van Tellinghen, V. Blomen, N. Domanitskaya, H. Ploegh, T. Brummelkamp, P. Borst, S. Rottenberg (Switzerland)	202
A high TRAIL-receptor clustering is able to overcome TRAIL resistance in pediatric bone sarcoma models <u>R. Guiho</u> , K. Biteau, J. Taurelle, V. Trichet, F. Tirode, M. Dominici, D. Heymann, F. Redini (France)	183	Extracellular superoxide dismutase supports tumorigenesis through autocrine-paracrine switch <u>M. Laukkanen</u> , F. Cammarota, K. Jaehyup, P. Hematti (Italy)	203
The inhibitory effects of an ethanol extract of Annona atemoya seeds on tumor-induced angiogenesis in hypoxia conditions <u>J.M. Yi</u> , J.S. Park, J. Lee, O.S. Bang, N.S. Kim (South Korea)	184	SOX2 and Hedgehog signaling: Partners in melanoma tumorigenesis <u>S. Pietrobono</u> , S. Pandolfi, R. Santini, V. Montagnani, M. Rivero, B. Stecca (Italy)	204
Molecular and functional traits of ovarian cancer stem cells <u>M. Lupia</u> , G. Beralot, S. Confalonieri, P.P. Di Fiore, N. Colombo, U. Cavallaro (Italy)	185	A potential novel metabolic symbiosis between acidic mesenchymal stem cells and melanoma cells S. Peppicelli, <u>E. Bianchini</u> , L. Calorini (Italy)	205
L1CAM: A new driver in tumor vasculature <u>F. Angiolini</u> , E. Magrini, F. Bianchi, A. Villa, P.P. Di Fiore, M. Mazzone, U. Cavallaro (Italy)	186	Biological evaluation of MRT-92, a novel antagonist of the SMOOTHENED receptor <u>R. Santini</u> , E. Petricci, F. Manetti, M. Taddei, B. Stecca (Italy)	206
Dual CXCR4 and e-selectin pharmacological inhibition reduces tumour growth and increases the sensitivity to docetaxel in experimental bone metastases of prostate cancer G.L. Gravina, A. Mancini, A. Colapietro, S. Delle Monache, A. Angelucci, A. Calgani, P. Sanità, W.E. Fogler, L. Magnani, <u>C. Festuccia</u> (Italy)	187		

	ABSTRACT NR.		ABSTRACT NR.
A novel small molecule IMP1338 induces apoptosis of human cancer cells by inducing p53-independent- S and G2/M cell cycle arrest <u>J. Ahn</u> , H. Ryu, B. Seo, J. Song (South Korea)	208	SerpinB3 and HIF2a expression in liver cancer cells: Mechanisms and prognostic significance <u>S. Cannito</u> , C. Turato, E. Morello, G.M. Villano, U. Cillo, E. Rovida, S. Colombatto, M.L. Martinez-chantar, P. Pontisso, M. Parola (Italy)	227
The chemokines GRO- α and IL-8 secreted from omentum promote aggressiveness of ovarian cancer cells <u>W.H. Tang</u> , H.Y.S. Ngan, D.W. Chan (Hong Kong)	209	Phosphatidylcholine-specific phospholipase C as new target for inhibiting proliferation and survival of tumor initiating cells in squamous carcinoma <u>S. Cecchetti</u> , I. Bortolomai, L. Mercurio, S. Canevari, F. Podo, S. Miotti, E. Iorio (Italy)	228
Role of microRNAs in regulating Met protein expression and invasiveness in papillary thyroid carcinoma <u>S. Scarpino</u> , C. Cippitelli, E. Cocco, G. Pepe, A. Di Napoli, S. Giglio, L. Ruco (Italy)	210	Preclinical study of afatinib in esophageal squamous cell carcinoma (ESCC) <u>H.H. Deng</u> , C.H. Wong, C.W.C. Hui, A.T.C. Chan, B.B.Y. Ma (Hong Kong)	230
OXPHOS inhibition and pentose phosphate pathway induction are early events priming preneoplastic lesions towards HCC development M. Kowalik, G. Guzzo, A. Morandi, A. Perra, S. Menegon, M.A. Angioni, S. Giordano, P. Chiarugi, A. Rasola, <u>A. Columbano</u> (Italy)	211	Preliminary study to evaluate the role of SERPINA1 (AAT) in OC and EC progression <u>A. Meloscia</u> , C. Baranello, M. Petrillo, G. Scambia (Italy)	231
CXCR4 role in ovarian cancer dissemination <u>A. Figueras</u> , E. Alsina-Sanchis, A. Vidal, A. Villanueva, F. Viñals (Spain)	212	Characterization of a human colon carcinoma HCT-8 cells with MDR phenotype <u>L. Cinci</u> , E. Bigagli, M. Coronello, A. Parenti, S. Paccosi, I. Carboni, D. Guasti, C. Luceri (Italy)	232
The TS3R domain of thrombospondin-1 affects tumor vascularization and improves response to chemotherapy <u>D. Pinessi</u> , A. Resovi, M. Lavinia, P. Borsotti, R. Giavazzi, M. Zucchetti, G. Tarabozetti (Italy)	213	The Anp32C oncogene is a novel client of Hsp90 and enhances cellular sensitivity to PU-H71 <u>Y. Yuzefovych</u> , R. Blasczyk, T. Huyton (Germany)	233
The telomeric protein TRF2 regulates tumor angiogenesis by affecting the secretome of cancer cells <u>P. Zizza</u> , E. Salvati, C. Cingolani, M. Porru, C. Leonetti, A. Biroccio (Italy)	215	Delta-tocotrienol induces ER stress-mediated apoptosis in human melanoma cells M. Marzagalli, <u>M. Montagnani Marelli</u> , R.M. Moretti, R. Comitato, G. Beretta, P. Limonta (Italy)	234
Effects of tumor-secreted miR-9 on human breast fibroblasts <u>S. Baroni</u> , M. Di Modica, I. Plantamura, E. D'Ippolito, C. Piovan, V.M. Iorio (Italy)	216	Role of exosome-associated miR-939 in breast cancer metastatic process <u>M. Di Modica</u> , P. Casalini, V. Regondi, S. Baroni, M.V. Iorio, M. Sandri, A. Zanetti, E. Tagliabue, T. Triulzi (Italy)	235
Hypoxia mediates the up-regulation of the plasminogen receptor S100A10 in cancer cells <u>N. Vasconcelos Conchinha</u> , M.R. Castanheira, S.A. Castaldo, P.A. Madureira (Portugal)	217	Characterization of the role of LMW-PTP in tumor onset <u>G. Lori</u> , G. Raugei, R. Marzocchini (Italy)	236
The AAA+ ATPase Ruvbl1 is a major regulator of liver metabolism and promotes hepatocellular carcinoma progression through the mTOR pathway <u>T. Mello</u> , F. Zanieri, O. Bereshchenko, E. Ceni, M. Tarocchi, G. Marroncini, S. Polvani, S. Tempesti, S. Milani, A. Galli (Italy)	218	Identification of novel putative Bcl-2 interacting proteins by mass spectrometry <u>S. D'Aguzzo</u> , M. Desideri, M. Di Martile, T. De Luca, D. Trisciuglio, A. Urbani, D. Del Bufalo (Italy)	237
Significance of Nrf2-Keap1 pathway in regulating RCC chemoresistance <u>C.W. Cheng</u> , C.J. Hsiao, B.C. Liu, J.D. Lin, T.K. Chao (Taiwan)	219	SCD1 as a prognostic marker and a therapeutic target for adenocarcinoma of the lung <u>A. Noto</u> , M.E. Pisanu, C. De Vitis, L. Fattore, D. Malpicci, M. Agostini, S. Morrone, G. Melino, G. Ciliberto, R. Mancini (Italy)	238
Tumor-associated macrophages-driven modulation of 5-fluorouracil effects on C26 colon carcinoma cells <u>L. Patras</u> , E. Licarete, L. Luca, A. Sesarman, M. Alupej, M. Banciu (Romania)	221	Use of prostate cancer cells as in vitro model for discovering miRNAs released by cells that developed docetaxel resistance L. Bascetta, M. Evangelista, G. Rainaldi, A. Mercatanti, <u>R. D'Aurizio</u> , F. Russo, M. Pellegrini, A. Altavilla, S. Bracarda, M. Rizzo (Italy)	239
LECT2 inhibits the intra-hepatic vascular invasion and metastasis of HCC by directly binding c-Met and disrupting its activation <u>C. Chen</u> , K. Hua, M. Hsiao, M. Kuo (Taiwan)	222	ANGPTL1/integrin $\alpha 1\beta 1$ axis represses SLUG-mediated cancer cell invasion and metastasis through miR-630 <u>T. Kuo</u> , J. Su, M. Kuo (Taiwan)	240
Resistance to hormone therapy alters both migration pattern and mechanical properties of breast cancer cells <u>K.E. Siatis</u> , E. Giannopoulou, D. Metsiou, G. Athanassiou, A. Theocharis, H.P. Kalofonos (Greece)	223	Studies on epithelial-mesenchymal transition and cancer stem cell's role in cisplatin response in ovarian cancer xenografts <u>F. Ricci</u> , F. Cuffanti, M. Fratelli, M. Broggin, G. Damia (Italy)	241
A novel biomarker for fighting malignant pleural mesothelioma A. Giacomino, M. Pirro, S. Morone, N. Lo Buono, S. Augeri, I. Rapa, L. Righi, M. Volante, <u>E. Ortolan</u> , A. Funaro (Italy)	224	miR-26a targets identification in prostate cancer cell lines using miRNA pull-out assay G. Berti, M. Evangelista, G. Rainaldi, F. Russo, R. D'Aurizio, M. Pellegrini, <u>M. Rizzo</u> (Italy)	242
Resistance to DNA damaging chemotherapy in cancer is associated with specific alterations in the nuclear protein compartment identified by Stable Isotope Labelling of Amino acids in Cell Culture (SILAC) proteomics <u>K.A. Menezes</u> , P. Cunnea, S. Lin, J. Kast, E.A. Stronach (United Kingdom)	225	miR-28-5p showed a tumor suppressive activity in DU-145 prostate cancer cells and regulated E2F6 G. Berti, M. Evangelista, G. Rainaldi, F. Russo, R. D'Aurizio, M. Pellegrini, <u>M. Rizzo</u> (Italy)	243
Crosstalk between TGF β and IGF signaling pathways in ovarian cancer orthotopic mouse models <u>E. Alsina-Sanchis</u> , A. Figueras, A. Vidal, A. Villanueva, F. Viñals (Spain)	226	Novel peptide inhibitors of CXCR4 directly affect the subset of lung cancer initiating cells and prevent their metastatic dissemination <u>G. Bertolini</u> , M. Moro, R. Caserini, C. D'Alterio, U. Pastorino, S. Scala, G. Sozzi, L. Roz (Italy)	245

	ABSTRACT NR.		ABSTRACT NR.
GREB1 is an estrogen-regulated gene which promotes ovarian cancer cell proliferation and tumour progression in mouse models <u>K.M. Hodgkinson</u> , B.V. Vanderhyden (Canada)	246	Metformin inhibits proliferation but does not induce death in colorectal cancer cells <u>M.V. Maiorana</u> , A. Mogavero, C. Bertan, F. Bozzi, M.A. Pierotti, M. Gariboldi (Italy)	364
Prostate cancer: Chemotherapy effects in cancer stem cells <u>S. Pagliaro</u> , E. Rovida, P. Dello Sbarba, P. Castelo-Branco, J.N. Moreira (Portugal)	247	A new strategy to prevent anthracycline-induced cardiotoxicity while improving anti-cancer activity <u>S. Cutts</u> , S. Pepe, T. Robinson, A. Rephaeli, A. Nudelman, C. Cullinane, D. Phillips, D. Rayner (Australia)	367
Phosphatidylcholine-specific phospholipase C inhibition as a new therapeutic approach to control triple-negative breast cancer cells proliferation P. Pisterzi, L. Mercurio, M.J. Caramujo, E. Iorio, F. Podo, <u>S. Cecchetti</u> (Italy)	248	Next generation sequencing to predict metastatic melanoma therapy response <u>R. Pinto</u> (Italy)	368
Anti-angiogenic property of monoolein against human cervical cancer cells: An animal model S. Rongpan, A. Jariyapongskul, <u>B. Wongsatayanon</u> (Thailand)	249	MiR-125b as potential prognostic circulating biomarker in metastatic melanoma patients treated with Temozolomide/ Fotemustine <u>S. De Summa</u> , R. Pinto, M. Guida, S. Strippoli, G. Guida, A. Azzariti, S. Tommasi (Italy)	369
Anoikis of colon carcinoma cells triggered by beta-catenin loss can be enhanced by Tumor Necrosis Factor Receptor 1 antagonists <u>K. Rosen</u> , B.H. Yoo, O. Masson, Y. Li, I.A. Khan, P. Gowda (Canada)	250	Activity of a STAT3 inhibitor in diffuse intrinsic pontine gliomas N.G. Olaciregui, A.M. Carcaboso, <u>N. Gene</u> (Spain)	371
Evaluation of Wnt receptor targeted theranostic nanoparticles in models of drug-resistant triple negative breast cancer <u>J. Miller-Kleinhenz</u> , X. Guo, H. Zhou, E. Bozeman, W. Qian, Y.A. Wang, A. Zelnak, R. O'Regan, L. Yang (USA)	251	Combined therapy with Histone deacetylase inhibitor and chemotherapy overcomes drug resistance in lung cancer cells <u>J. Kwee</u> , A.C.S. Ferreira, C.C.V. Gallo, L.F.R. Silva, R.A. Fernandes (Brazil)	372
Cross talk between bioenergetic and phosphatidylcholine metabolism in human glioma cells M. Rinaudo, L. Mercurio, E. Zulato, S. Cecchetti, G. Carpinelli, S. Indraccolo, F. Podo, <u>E. Iorio</u> (Italy)	252	A Goodpasture antigen-binding protein kinase inhibitor to treat drug-resistant invasive lung and breast cancer <u>J. Saus</u> , F. Revert, A. Artigot, R. Blasco, J.F. Sanz-Cervera, E. Pérez-Payá, E. López-Pascual, A.M. Pérez-Sastre, R. Gozalbo-Rovira, F. Revert-Ros (Spain)	373
miR155 drives metabolic and motile reprogramming of ER positive breast cancer cells following long-term estrogen deprivation <u>A. Morandi</u> , M. Bacci, L.A. Martin, M.L. Taddei, G. Pintus, E. Giannoni, P. Chiarugi (Italy)	253	Lysosomotropic REV-ERB β antagonism as an innovative anticancer strategy L. Ercolani, C. Parodi, C. De Mei, <u>A. Ferrari</u> , E. Torrente, R. Scarpelli, B. Grimaldi (Italy)	374
Characterization of adrenocortical carcinoma proteomic profile G. Poli, E. Ceni, <u>R. Armignacco</u> , T. Ercolino, L. Canu, G. Baroni, G. Nesi, A. Galli, M. Mannelli, M. Luconi (Italy)	254	Interaction between mitochondrial and nuclear DNA in cisplatin resistance: Use of transmitochondrial hybrids <u>D. Catanzaro</u> , G. Orso, C. Giordano, C. Vianello, L. Caparrotta, E. Ragazzi, C. Frezza, M. Montopoli (Italy)	375
EP3 receptor on platelets modulates Prostaglandin E2-mediated angiogenic factors release F. Finetti, M. Ziche, <u>S. Donnini</u> (Italy)	255	Depletion of mitochondrial DNA modulates cellular sensitivity to cisplatin <u>C. Vianello</u> , D. Catanzaro, E. Ragazzi, L. Caparrotta, M. Montopoli (Italy)	376
Experimental/Molecular Therapeutics, Pharmacogenesis I			
MK2 inhibitor targeting microtubules: Novel drug candidate for glioblastoma therapy <u>F. Gurgis</u> , M. Akerfeldt, C. Wong, B. Heng, G.J. Guillemin, M. Chircop, L. Munoz (Australia)	359	Evolution of pediatric solid tumors towards a limited drug distribution phenotype <u>C. Monterrubio</u> , J. Mora, A.M. Carcaboso (Spain)	378
A novel mitocan compound selectively and efficiently suppresses resistant Her2high breast carcinomas <u>K. Sachaphibulkij</u> , K. Prokopova, L.F. Dong, E.A. Pasdar, B. Endaya, B. Yan, A. Bezawork-Geleta, J. Neuzil (Australia)	360	¹ H-NMR to detect intracellular metabolites in living human ovarian cancer cell lines D. Catanzaro, M. Bellanda, E. Ragazzi, C. Vianello, S. Mammi, L. Caparrotta, <u>M. Montopoli</u> (Italy)	379
Targeted inhibition of casein kinase II enhances IKZF1-mediated repression of PI3K pathway in primary acute lymphoblastic leukemia xenografts <u>S. Dovat</u> , C. Song, C. Gowda, Y. Ding, S. Muthusami, E. Dovat, D. Desai, S. Amin, J.L. Payne (USA)	361	Role of miR-483-3p in platinum drug-resistance of human ovarian carcinoma cells <u>L. Gatti</u> , N. Arrighetti, G. Cossa, L. De Cecco, N. Carenini, E. Corna, P. Gandellini, N. Zaffaroni, P. Perego (Italy)	380
Structural activity studies on L-sugar derived glycosylated antitumor ether lipids: Evaluation of antitumor effects on cancer cell lines and cancer stem cells <u>M. Ogunsina</u> , P. Samadder, G. Arthur, F. Schweizer (Canada)	362	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS through the upregulation of the major mitochondrial porin VDAC1 and the modulation of c-myc-Nrf2-Keap1 pathway <u>A. Leone</u> , M.S. Roca, C. Vitagliano, R. Mancini, G. Ciliberto, F. Bruzzese, A. Budillon (Italy)	381
Proteomic study highlights the anticancer effects of thienotriazolodiazepines. Role of kinoma inhibition E. Ceni, S. Polvani, M. Tarocchi, C. Malentacchi, G. Marroncini, <u>T. Mello</u> , S. Tempesti, S. Milani, A. Galli (Italy)	363	Preclinical activity of the repurposed drug Auranofin in classical Hodgkin Lymphoma M. Celegato, C. Borghese, N. Casagrande, M. Mongiat, X.U. Kahle, A. Colombatti, <u>D. Aldinucci</u> (Italy)	382

	ABSTRACT NR.		ABSTRACT NR.
Aurora kinases A and B are potential therapeutic targets in KRAS-induced lung cancer <u>E.O. Dos Santos</u> , M.N. Aoki, T.C.C. Lobo, E. Levantini, D.S. Bassères (Brazil)	383	The novel multi-kinase inhibitor EC-70124 acts a dual inhibitor of NF- κ B and STAT3 signaling in prostate cancer stem cells G. Civenni, P. Costales, C. Dallavalle, D. Albino, N. Longoni, L. Nunez, F. Moris, G. Carbone, <u>C. Catapano</u> (Switzerland)	402
Trabectedin differentially affects ETS fusion genes binding to IGF-1R promoter in Ewing sarcoma and prostate cancer C. Mancarella, C. Garofalo, M.C. Manara, I. Casanova-Salas, J.A. Lopez-Guerrero, M. D'Incalci, <u>K. Scotlandi</u> (Italy)	384	Glutathione (GSH) underlies carboplatin resistance of ovarian clear cell carcinoma (OCCC)- related to hepatocyte nuclear factor 1b (HNF1b) <u>F. Coelho</u> , S. Gouveia-Fernandes, L. Gonçalves, C. Nunes, I. Faustino, F. Silva, A. Félix, S. Pereira, J. Serpa (Portugal)	403
Chemosensitisation of human breast carcinoma cell line MDA-MB-435S to vincristine and paclitaxel by silencing integrins alpha v and alpha 4 <u>N. Stojanovic</u> , D. Majhen, A. Dekanic, K. Ferencak, I. Bardak, M.T. Tomicic, M. Christmann, M. Osmak, A. Ambriovic-Ristov (Croatia)	386	Identification of amplified genes in lapatinib resistant HER2-positive breast cancer cells <u>N. Conlon</u> , M. McDermott, N. O'Brien, J. Dering, D. Slamon, J. Crown, N. O'Donovan (Ireland)	404
Role of the receptor tyrosine kinase Axl in the aggressive features of platinum-resistant ovarian carcinoma cells <u>C. Corno</u> , N. Arrighetti, L. Gatti, G. Cassinelli, N. Carenni, E. Corna, N. Zaffaroni, C. Lanzi, P. Perego (Italy)	387	Effect of Palbociclib (CDK 4/6 inhibitor) on breast cancer cell growth <u>L. Coppola</u> , M. Montanari, M.R. Carbone, S. De Placido, B.M. Veneziani (Italy)	405
Role of SR-BI and multidrug-resistance P glycoprotein in controlling cholesteryl ester uptake from high density lipoproteins: Are HDLs promising carriers for anticancer drugs? F. Angius, <u>S. Spolitu</u> , S. Uda, A. Frau, S. Deligia, A. Lacko, N. Sabnis, B. Batetta (Italy)	388	Oleocanthal, a phenolic compound of extra-virgin olive oil, inhibits cell growth and induces apoptosis in hepatocellular carcinoma cells <u>A. Cusimano</u> , A. Azzolina, G. Augello, M.R. Emma, D. Balasus, A.B. Smith III, G. Montalto, M. Cervello (Italy)	406
Wnt/ β -catenin signalling inhibition is a potential new therapeutic strategy in soft tissue sarcomas <u>A. Obrador</u> , E. Martinez, S. Calabuig-Fariñas, R. Ramos, I. Felipe-Abrio, J. Martín, R. Alemany (Spain)	389	Cellular and molecular characterization of 5-Fluorouracil (5-FU) induced toxicity on human cardiomyocytes and endothelial cells <u>A. Albini</u> , C. Focaccetti, A. Bruno, E. Magnani, E. Principi, C. Masini, E.O. Bucci, G. Finzi, F. Sessa, D.M. Noonan (Italy)	407
Synergistic antitumor activity of sorafenib and Akt Inhibitors <u>T. Ersahin</u> , I. Durmaz, R. Cetin-Atalay (Turkey)	390	Development of novel anti metastatic cancer therapeutics T. Humphries-Bickley, L. Castillo-Pichardo, L. Borrero-Garcia, L.A. Cubano, E. Hernandez, C. Vlaar, <u>S. Dharmawardhane</u> (Puerto Rico)	408
Antibody dependent cellular cytotoxicity: An effective strategy to target cutaneous melanoma cells that acquired resistance to BRAF inhibition E. Muraro, E. Fratta, A. Rizzo, E. Comaro, F. Colizzi, R. Dolcetti, <u>L. Sigalotti</u> (Italy)	391	In vitro resistance to 3rd generation EGFR tyrosine kinase inhibitors <u>N. Drobnitzky</u> , S. Bokobza, F. Cahill, A. Devery, Y. Jiang, L. Madia Lourenco, A. Mumín, A. Weber, A. Ryan (United Kingdom)	409
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening <u>M.C. Anania</u> , F. Gasparri, E. Cetti, I. Fraietta, C. Miranda, M. Mazzoni, R. Colombo, A. Galvani, M.A. Pierotti, A. Greco (Italy)	392	High expression of EGFR and low expression of ERBB3, within AXL-high/MITF-low melanomas, identify tumors intrinsically resistant to BRAF inhibition <u>M. Dugo</u> , G. Nicolini, I. Bersani, A. Tomassetti, S. Canevari, A. Anichini, M. Sensi (Italy)	410
The role of ALDH1 in chemoresistance of colon cancer cells <u>Z. Kozovská</u> , A. Patsalias, E. Duriníková, M. Matúšková, L. Kucerová (Slovak Republic)	394	An Egyptian plant extract Factor XY exhibits potent cytotoxic effects against bladder and prostate cancer <u>L. El-sawy</u> , G. Lorenzatti, J.R. Rubin, K.C. Day, A.S. Emamdjomeh, A. Chou, A.L. Cates, M. El-sawy, M.L. Day (USA)	411
Overcoming acquired EGFR inhibitor resistance in NSCLC with targeted beam irradiation in combination with targeted agents <u>A. McKenzie</u> , N. Papadopoulou, L. Page, S. Jiang, J. Wrigley, Y. Yin, Q. Shi, M. Page, A. Treverton, R. Kumari (United Kingdom)	395	miR-199 enforced expression inhibits tumor growth in a HCC transgenic mouse model <u>E. Callegari</u> , L. D'Abundo, B. Elamin, C. Bassi, F. Moshiri, B. Zagatti, S. Blandamura, S. Sabbioni, M. Negrini (Italy)	412
Cancer cells with alternative lengthening of telomeres are more sensitive to DNA damage by anti-sense telomere transcripts S. Sampl, T. Kreilmeier, D. Mejr, <u>K. Holzmann</u> (Austria)	396	A genetic signature of drug synergy: XPO1 inhibition and cisplatin overcome chemoresistance in ovarian cancer <u>B.R. Evans</u> , J.N. Billaud, T.R. Silvers, J. Garcia, S.V. Koduru, G. Pandey, A.J. Sharp, S. Shacham, P.R. Dottino, J.A. Martignetti (USA)	413
Acquired AKT drug resistance is associated with altered cap-dependent protein translation <u>D.T. Akan</u> , M.I. Walton, M.D. Garrett (United Kingdom)	397	HER3 and MEK dual targeting may overcome HER3-dependent chemo-resistance of colon cancers <u>R. Falcioni</u> , G. Bon, A. Verdina, R. Loria, A. Mastrofrancesco, S. Soddu, M. Milella (Italy)	414
Axl receptor kinase is up-regulated in metformin resistant LNCaP prostate cancer cells <u>J. Bertino</u> , N. Bansal, P. Mishra, M. Stein, R.S. Dipaola (USA)	398	DNA double-strand break repair in primary cultures of patient-derived ovarian carcinoma xenografts <u>F. Guffanti</u> , J. Kaufmann, F. Bizzaro, F. Ricci, M. Ganzinelli, M. Lupi, R. Giavazzi, L. Wiesmüller, G. Damia (Italy)	415
Base Excision Repair modulation of cisplatin activity in KRAS mutated NSCLC cells <u>E. Caiola</u> , R. Frapolli, M. Lupi, R. Valerio, M.C. Garassino, M. Broggin, M. Marabese (Italy)	400	Molecular determinants of response to PI3K and K-RAS pathways inhibitors <u>A. Iezzi</u> , E. Caiola, M. Marabese, L. Carrassa, M. Broggin (Italy)	418
Caveolin-1 levels are crucial for the anti-apoptotic role of Fas in chemoresistant colon cancer cells M. Fontcuberta, C. Rodríguez, J. Casamitjana, M. Balada, S. Pizarro, E. Enreig, P. Gascón, F.J. Casado, E. Ametller, <u>N. Carbó</u> (Spain)	401		

ABSTRACT NR.

ABSTRACT NR.

Anti-VEGF therapy elicits metabolic evolution of tumors M. Curtarello, E. Zulato, G. Nardo, S. Valtorta, A. Rasola, W. Mueller-Klieser, A. Amadori, R.M. Moresco, <u>S. Indraccolo</u> (Italy)	419	Improving precision of BRAF-targeted therapies to personalize melanoma treatments <u>H. Widlund</u> (USA)	437
Rapid induction of doxorubicin resistance in connected microenvironment elucidates novel molecular mechanisms <u>Y. Jun</u> , S. Kim, M. Chi, H. Hoa, S. Park, R.H. Austin, S. Lee (South Korea)	420	Bispecific CD73 x CD38 monoclonal antibody as a potential tool to overcome adenosine-mediated immunosuppression A. Zito, A. Chillemi, V. Quarona, G. Mandili, A. Cassone, <u>A.L. Horenstein</u> , F. Malavasi (Italy)	438
Acquisition of drug-resistance causes mesenchymal-to amoeboid transition (MAT) in epithelial ovarian cancer cells (OCCs) <u>A. Kapoor</u> , S. Sen (India)	421	A phase II study of metronomic chemotherapy (MC) with bevacizumab in advanced non-squamous non-small cell lung cancer (NSCLC): A novel strategy to delay drug resistance <u>F. Robert</u> , B.S. Jones, M.S. Jerome (USA)	439
Cellular & molecular mechanisms of drug resistance in cancer cells mutated for Fbxw7 - tumour suppressor gene <u>F. Lorenzi</u> , R. Babaei-Jadidi, A.S. Nateri (United Kingdom)	422	Transcriptional control of pancreatic cancer and small molecule modulators of transcription <u>W. Priebe</u> , A. Jayakumar, V. Radjendirane, J. Fleming, A. Rusin, R. Zielinski, S. Skora, Y. Kang, I. Fokt (USA)	440
The c-Met targeting antibody MM-131 reverses HGF-induced tumor cell resistance to standard-of-care drugs <u>K. Masson</u> , A. Fulgham, M. Gollvik, A. Raue, J. Casaletto, A. Abu-Yousif, S. Chattopadhyay, V. Moyo, G. MacBeath (USA)	423	Chronic myeloid leukemia stem cells are sensitive to the pharmacological inhibition of hypoxia-inducible factor-1a <u>G. Cheloni</u> , M. Tanturli, N. DeSouza, I. Tusa, Y. Shan, E. Rovida, S. Li, P. Dello Sbarba (Italy)	441
Activation of MAPK via loss of the tumour suppressor gene NF1 confers resistance to the SRC inhibitor Saracatinib (AZD0530) in epithelial ovarian cancer <u>N. McGivern</u> , N. McCabe, R.D. Kennedy (United Kingdom)	424	A role for ABCG2 beyond drug transport: Regulation of autophagy <u>K. Scotto</u> , V.S. Victor Jin, R. Ding (USA)	442
Flubendazole as potential anti-neuroblastoma therapy option <u>M. Michaelis</u> , B. Agha, F. Rothweiler, N. Löschmann, Y. Voges, F. Westermann, M.N. Wass, J. Cinatl (United Kingdom)	425	PORCN inhibition is effective therapy for Wnt-addicted genetically defined cancers B. Madan, K. Zhiyuan, N. Harmston, E. Petretto, J. Hill, T.H. Keller, M.A. Lee, A. Matter, <u>D.M. Virshup</u> (Singapore)	443
The Resistant Cancer Cell Line (RCCL) collection: Cell lines with acquired drug resistance <u>M. Michaelis</u> , M.N. Wass, J. Cinatl (United Kingdom)	426	Strategy for synchronous and multiple liver metastases <u>S. Osada</u> , S. Matsui, Y. Sasaki, K. Yoshida (Japan)	444
Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy <u>M. Pellegrino</u> , F. Mancini, R. Lucà, A. Coletti, I. Manni, E. Teveroni, M. Buttarelli, L. Fici, A. Macchiarulo, F. Moretti (Italy)	427	Biological characterization of nanocomposite hydrogels F. Finetti, E. Terzuoli, R. Barbucci, <u>S. Donnini</u> , M. Ziche, L. Morbidelli (Italy)	447
CCDC6 protein expression is reduced in Non Small Cell Lung Cancers (NSCLC) by post-translational regulation mechanisms: New therapeutic implications F. Morra, <u>E. Merolla</u> , R. Visconti, A. Cerrato, G. Guggino, R. Monaco, S. Staibano, A. Celetti (Italy)	428		
Cytokine mediated host-tumour interactions lead to treatment resistance <u>R. Patel</u> , C. Loveridge, J. Fleming, I. Ahmad, H. Leung (United Kingdom)	429		
Investigation of the effects of HMG-CoA reductase inhibitors and mTOR inhibitors alone or as a novel combination in breast cancer cells <u>V. Petroni</u> , M.T. Camilleri Podesta, A.G. Fenech, R. Formosa, G. Grech (Malta)	430		
ErbB3 targeting to overcome resistance to tyrosine kinase inhibitors. <u>G. Roscilli</u> , A. Noto, C. De Vitis, A. Ricci, S. Mariotta, M.R. Giovagnoli, F.F. Ferrara, L. Aurisicchio, G. Ciliberto, R. Mancini (Italy)	431		
Different responses of human ovarian carcinoma cells to the gene therapy mediated by genetically modified mesenchymal stem cells <u>L. Toro</u> , R. Bohovic, L. Kucerova (Slovak Republic)	433		
Differential effects of acteoside in normal and cancer cells C. Cheimonidou, A. Argyropoulou, P. Samara, E.N. Tsakiri, I. Papassideri, P. Polychronopoulos, O.E. Tsitsilonis, N. Aligiannis, A.L. Skaltsounis, <u>I.P. Trougakos</u> (Greece)	434		
Synthesis and characterization of polyethylene glycol coated magnetic nanoparticles and their use for anti-cancer drug delivery M. Erdem, S. Yalcin-Azarkan, <u>C. Urfali-Mamatoglu</u> , U. Gunduz (Turkey)	435		
Therapeutic potential of a novel C-terminal inhibitor of Hsp90 encapsulated in liposomes F. Sauvage, S. Franzé, A. Bruneau, S. Messaoudi, M. Alami, E. Brotin, S. Lesieur, G. Barratt, <u>J. Vergnaud-Gauduchon</u> (France)	436		
		Molecular and Genetic Epidemiology I	
		Prevalence of human papillomavirus in laryngeal and hypopharyngeal squamous cell carcinomas in Northern Spain <u>S. Alvarez-Teijeiro</u> , J.P. Rodrigo, M. Hermsen, M.A. Villaronga, F.J. Hermida-Prado, S.T. Menéndez, R.H. Brakenhoff, P.J.F. Snijders, D.A.M. Heideman, J.M. García-Pedrero (Spain)	535
		Immunohistochemical markers of distant metastasis in laryngeal and hypopharyngeal squamous cell carcinomas <u>M. Villaronga Torres</u> , J.P. Rodrigo, P. Martínez, E. Allonca, L. Alonso-Durán, S.T. Menéndez, S. Alvarez-Teijeiro, F.J. Hermida-Prado, A. Astudillo, J.M. García-Pedrero (Spain)	536
		Correlation among APC and MUTYH mutational spectrum, expression and phenotype in Italian patients with familial polyposis and/or colorectal cancer F. Fantini, G.M. Aceto, S. De Iure, G. Palka, R. Valanzano, P. Di Gregorio, M. Di Nicola, P. Battista, A. Cama, <u>M.C. Curia</u> (Italy)	538
		Prevention and Early Detection I	
		Chemopreventive and chemosensitizing properties of N-(4-hydroxyphenyl) retinamide on Cancer Stem Cells (CSCs) <u>A. Bruno</u> , D. Bartolini, K. Dallaglio, B. Bassani, S. Canali, D.M. Noonan, A. Albin (Italy)	550
		miRandola database: The future of non-invasive diagnosis through circulating miRNA biomarkers <u>F. Russo</u> , S. Di Bella, G. Nigita, A. Laganà, F. Scoyni, A. Pulvirenti, R. Giugno, M. Pellegrini, A. Ferro (Italy)	551
		Radiobiology/Radiation Oncology I	
		PARP inhibition radiosensitizes human soft tissue sarcoma cells <u>M. Sottili</u> , C. Gerini, M. Mangoni, A. Montalbano, I. Desideri, D. Greto, R. Capanna, G. Beltrami, D. Campanacci, L. Livi (Italy)	556

	ABSTRACT NR.		ABSTRACT NR.
Effect of alpha lipoic acid on radiation-induced thyroid injury in rats <u>J. Jung</u> , J. Kim, S. Woo, B. Jeong, K. Kang, J. Hahm, J. Jung, S. Kim (South Korea)	557	TRIB2 promotes resistance to chemotherapeutics by deregulating the AKT signalling network <u>R. Hill</u> , P.A. Madureira, L. Colaço, M. Santos, I. Baptista, S. Ugurel, M. Isbilen, A. Gure, W. Link (Portugal)	585
The DNA damage-induced phosphoproteome is modulated by inhibition of the MET receptor <u>M. Medova</u> , A. Bensimon, P. Francica, J.P. Koch, A.A. Glück, E. Orlando, D.M. Aebersold, R. Aebersold, Y. Zimmer (Switzerland)	558	What about a dual inhibition of epidermal growth factor receptor and notch pathway in non-small cell lung cancer cells? <u>A. Lampropoulou</u> , E. Giannopoulou, A. Theocharis, H. Kalofonos (Greece)	587
Protective effects of alpha lipoic acid on radiation-induced salivary gland injury in rats <u>S. Woo</u> , G.M. Kim, J.H. Jung, B.K. Jeong, J.R. Hahm, J.H. Kim (Korea)	559	Combination treatment with All-Trans Retinoic Acid prevents cisplatin-induced enrichment of CD133+ tumor initiating cells and reveals heterogeneity of cancer stem cell compartment in lung cancer <u>M. Moro</u> , G. Bertolini, U. Pastorino, L. Roz, G. Sozzi (Italy)	588
MET targeting sensitizes glioblastoma stem-like cells to ionizing radiation <u>E. De Bacco</u> , A. D'Ambrosio, E. Casanova, R. Neggia, R. Albano, F. Orzan, E. Garibaldi, P. Gabriele, P.M. Comoglio, C. Boccaccio (Italy)	560	Harnessing reactive oxygen species and cell death pathways for the treatment of pediatric T-ALL <u>M. Silic-Benussi</u> , I. Cavallari, F. Rende, L. Urso, S. Minuzzo, G. Basso, S. Indraccolo, V. Ciminale (Italy)	589
The role of neutrophil myeloperoxidase in radiation-induced lung damage <u>L. Madia Lourenco</u> , F. Cahill, N. Drobnitzky, Y. Jiang, A. Mumin, A. Weber, A. Ryan (United Kingdom)	562	mPGES-1 and EGFR in prostate cancer progression F. Finetti, E. Terzuoli, L. Bazzani, M. Ziche, <u>S. Donnini</u> (Italy)	590
Signalling Pathways I		Translational Research I	
Peptide-guided targeting of GPR55 for new therapeutic strategies of cancer E. Iaccino, M. Mangini, M.G. Mosca, S. Mimmi, I. Quinto, G. Scala, <u>S. Mariggio</u> (Italy)	570	The "panta rhei" of breast cancer: Gene expression timeline analysis during progression of microinvasive breast cancer microenvironment <u>F. Lessi</u> , C. Scatena, P. Aretini, M. Menicagli, S. Franceschi, V. Ortenzi, M. La Ferla, G. Bevilacqua, A.G. Naccarato, C.M. Mazzanti (Italy)	614
Integrated quantitative experimental and computational approach for characterizing non-genetic drug resistance mechanisms <u>A. Claas</u> , J. Downey, D. Lauffenburger (USA)	571	Dual inhibition of PI3K and mTOR strongly induces apoptosis of uveal melanoma cell lines and leads to tumor stasis in vivo in patient-derived xenografts <u>M. Schoumacher</u> , N. Amirouchene-Angelozzi, F. Nemati, A. Dahmani, C. Raymondie, D. Gentien, D. Decaudin, S. Roman-Roman (France)	615
Effects of KEAP1 genetic and epigenetic silencing in SCLC cell lines <u>L. Muscarella</u> , A. Sparaneo, D. Trombetta, T. Balsamo, M. Copetti, M. Sanchez-cespedes, E. Maiello, P. Graziano, V.M. Fazio (Italy)	572	Prognostic microRNA signature in malignant pleural mesothelioma patients <u>S. Coco</u> , A. Truini, C. Genova, E. Nadal, M.G. Dal Bello, I. Vanni, A. Alama, E. Rijavec, D.G. Beer, F. Grossi (Italy)	616
Nrf2-keap1 axis: Uncovers molecular profile in Lung Carcinoids <u>A. La Torre</u> , A. Sparaneo, P. Graziano, D. Di Candia, M. Copetti, M. Bisceglia, S. Pizzolitto, E. Maiello, V.M. Fazio, L.A. Muscarella (Italy)	573	Metabolic and morphofunctional imaging of trabectedin treatment effects in a preclinical model of HER-2 overexpressing ovarian cancer <u>E. Iorio</u> , G. Palombelli, F. Ginnari Satriani, A. Ricci, M. Bagnoli, S. Canevari, L. Liliac, F. Podo, D. Mezzanzanica, R. Canese (Italy)	617
The Extracellular signal-regulated Kinase 5 is required for human melanoma cell growth I. Tusa, S. Pandolfi, L. Borgognoni, S. Gagliardi, B. Stecca, <u>E. Rovida</u> (Italy)	576	Paclitaxel drives response to combination therapy with bevacizumab in ovarian cancer preclinical models <u>F. Bizzaro</u> , E. D'agostini, A. Decio, F. Falchetta, E. Erba, P. Ubezio, R. Giavazzi (Italy)	618
RET targeting with small kinase inhibitors in ER positive breast cancer xenografts sensitive to aromatase inhibitors E. Andreucci, P. Francica, T. Fearn, L.A. Martin, C.M. Isacke, <u>A. Morandi</u> (Italy)	577	Uncovering mechanisms of resistance to cetuximab by insertional mutagenesis in heterotopically-engrafted human colorectal cancers <u>V. Pirazzoli</u> , R. Biavasco, G. Spinozzi, A. Bertotti, L. Trusolino, E. Montini (USA)	619
Interplay between metabolism and the Hippo signaling pathway in T cell leukemia <u>K. Valis</u> , P. Talacko, J. Novakova, P. Novak (Czech Republic)	579	Thymidylate-synthase poly-epitope peptide vaccination in pretreated metastatic cancer patients; a multi-arm phase Ib trial P. Correale, C. Botta, <u>E.C. Martino</u> , C. Gandolfo, G.M. Guidelli, M.G. Rossetti, E. Dreassi, P. Tagliaferri, L. Pirtoli, M.G. Cusi (Italy)	620
Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models <u>R. Chilà</u> , F.G. Guffanti, T.H. Hall, F.R. RICCI, M.B. Broggin, G.D. Damia (Italy)	580	Identification of circulating miRNAs in DIPG patients as predictors of response to targeted therapy and as classifiers of clinical outcome <u>S. Canevari</u> , M. Massimino, A. Anichini, E. Marchesi, R. Mortarini, V. Biassoni, E. Schiavello, L. De Cecco (Italy)	621
miR-30a inhibits endothelin A receptor expression and acquisition of chemoresistance of ovarian carcinoma <u>R. Sestito</u> , R. Cianfrocca, L. Rosanò, E. Semprucci, G. Ferrandina, V. Di Castro, A. Bagnato (Italy)	581	Metastasis- related characterisation of tumorspheres derived from circulating epithelial tumor cells (CETCs) in colorectal cancer patients <u>M. Pizon</u> , D. Zimon, U. Pachmann, K. Pachmann (Germany)	622
Overcoming TKI resistance in chronic myeloid leukemia and EGFR mutant glioblastoma by targeting a Nox2-Egr1-Fyn pathway <u>J. Chandra</u> , B. Johnson, M. Irwin (USA)	583		
PGE2 via EP4 receptor trans-activates the Colony-Stimulating Factor-1 (CSF-1) receptor and via the kinase ERK1/2 synergizes with CSF-1 in the induction of macrophage migration G. Digiacomo, I. Tusa, M. Ziche, P. Dello Sbarba, S. Donnini, <u>E. Rovida</u> (Italy)	584		

ABSTRACT NR.

ABSTRACT NR.

- Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR-mutant lung adenocarcinoma** 623
V. Pirazzoli, D. Ayeni, C.B. Meador, B.G. Sanganahalli, F. Hyder, S. Goldberg, W. Pao, K. Politi (USA)
- Gene expression profile of primary squamocellular oral cavity tumors to disclose biological features in nodal invasion** 624
L. De Cecco, F. Perrone, B. Cortelazzi, S. Alfieri, L. Pala, M. Giannoccaro, S. Pilotti, L. Licitra, P. Bossi, S. Canevari (Italy)
- Cationic amphiphilic antihistamines sensitize non-small cell lung cancer cells to chemotherapy and improve the survival of cancer patients** 625
A.M. Ellegaard, A. Anand, C. Dehlendorff, S. Tvingsholm, L. Cederkvist, N. Petersen, J. Nylandsted, S. Friis, M. Jäättelä (Denmark)
- Effect of c-MET and MTOR inhibitors in malignant pleural mesothelioma (MPM) cells** 626
L. Oguh, D. Ranatunge, V. Agarwal, A. Campbell, M.J. Lind, L. Cawkwell (United Kingdom)
- Epigenetic sensitization of respiratory tract cancer cells to paclitaxel** 627
A.S. Al-Khafaji, J.M. Risk, R.J. Shaw, J.K. Field, T. Liloglou (United Kingdom)
- Molecular profile based approach in targeted therapy for Head and Neck Cancer- A xenograft study** 628
R. Reddy, B. Ramachandran, S. Rajendran, V. Dhavale, H. Vardhan, N. Hedne, V. Kekatpure, A. Jayaprakash, A. Suresh, M.A. Kuriakose (India)
- Discovery and validation of predictive protein biomarker candidates in CRC** 629
N. Lange, F.T. Unger, H. Juhl, K.A. David (Germany)
- A plasma microRNA-based test predicts lung cancer outcome and disease status at follow-up in low-dose computed tomography (LDCT) screening trials** 630
M. Boeri, S. Sestini, C. Galeone, A. Marchiano, G. Pelosi, N. Sverzellati, C. La Vecchia, G. Sozzi, U. Pastorino (Italy)
- Role of AGTR1 in the response to bevacizumab treatment in solid tumors** 631
F. Conde, N. Galera, A. Valverde, A. Canas, V. Hernandez, C. López-Pedrerá, E. Aranda, A. Rodríguez-Ariza, J. De la Haba (Spain)
- Molecular differences between cabazitaxel and docetaxel resistance in castration-resistant prostate cancer cells** 632
N. Jimenez, M. Marin-Aguilera, O. Reig, S. Garcia-Recio, P. Gascon, A. Prat, B. Mellado (Spain)
- Aberrant β -catenin activation drives aggressive and treatment-resistant prostate cancer** 633
E.A. Brzezinska, R. Patel, I. Ahmad, M. Gao, O.J. Sansom, H.Y. Leung (United Kingdom)
- Morphological and metabolic effects detected by in vivo MRI and MRS in a D16HER2 variant of HER2-positive breast cancer model after target treatment** 634
R. Canese, M. Borghi, E. Iorio, G. Carpinelli, F. Lozupone, T. Azzarito, S. Fais, A. Koschorke, E. Tagliabue, S. Pupa (Italy)
- hERG1 potassium channels expression in metastatic colorectal cancer** 635
E. Lastraioli, L. Antonuzzo, L. Bencini, T. Lottini, J. Iorio, M. Farsi, A. Coratti, L. Boni, F. Di Costanzo, A. Arcangeli (Italy)
- Novel chemosensitive single nucleotide polymorphism marker in metastatic colorectal cancer treated with bevacizumab** 636
S. Roh, Y. Kwon, I. Park, J. Kim (South Korea)
- Optimization of novel metabolomic approach for detection of new potential biomarkers for prostate cancer** 637
D. Farioli, D. Daniela Briga, I. Sogno, M. Chiappelli, S. Caraffi, M. Conti, P. Consonni, A. Bruno, D.M. Noonan, A. Albini (Italy)
- Diagnostic and prognostic impact of microRNA levels in serum of high-grade serous ovarian carcinoma patients** 638
P. Todeschini, E. Salviato, A. Ravaggi, M. Ferracin, E. Sartori, M. Negrini, M. D'Incalci, S. Marchini, E. Bignotti, C. Romualdi (Italy)
- Effect of phenanthroline and bipyridine derivatives and their respective Ru(II) metal complexes on human AML cell lines** 639
D. Azar, R. Khnayzer, M. El-Sibai, R. Abi-Habib (Lebanon)
- Megakaryocyte differentiation and proplatelet formation from long term cryopreserved CD34+ cells: From laboratory to clinic** 640
M. Battiston, F. Agostini, S. Zanolin, M. Michieli, E. Lombardi, D. De Zanet, L. De Marco, A. Balduini, C. Durante, M. Mazzucato (Italy)
- IGFBP-3 influences breast cancer metastasis and experimental colitis** 642
M. Blouin, D. Yancu, E. Birman, L. Florianova, M. Zakikhani, M. Pollak (Canada)
- Expression of different biomarkers on circulating tumor cells from patients with metastatic breast cancer** 643
M. Carbone, M. Giuliano, M. Montanari, G. Arpino, L. Coppola, C. Garbi, S. De Placido, B.M. Veneziani (Italy)
- Dissecting the role of microenvironment-driven activation of HER2 in BC relapse** 644
F. Citron, L. Fabris, S. Berton, I. Segatto, S. D'Andrea, G. Baldassarre, B. Belletti (Italy)
- Gastric cancer in the age of targeted agents: Identification and validation of novel therapeutic strategies through the generation of a patient-derived xenografts platform** 645
S. Corso, M. Apicella, S. Menegon, M. Cargnelutti, M.S. Scalzo, R. Reddavid, P. Cassoni, A. Sapino, M. Degiuli, S. Giordano (Italy)
- Gene expression analysis of five tumor-associated markers in CTC isolated from Bulgarian metastatic breast cancer patients** 646
D. Dacheva, S. Valev, M. Taushanova, K. Timcheva, V. Mitev, R. Kaneva, A. Mitkova (Bulgaria)
- Institution of head and neck paragangliomas cell lines and testing of drugs active on tumor metabolism** 647
R. Florio, L. De Lellis, D. Verzilli, V. Di Giacomo, M. Basile, M.C. Di Marcantonio, G. Mincione, F. Verginelli, R. Mariani Costantini, A. Cama (Italy)
- Analysis of biodistribution and biological effects associated with environmental exposition to multi-walled carbon nanotubes (MWCNTs) in a murine model** 648
D. Noonan, A. Pagani, A. Bruno, T. Rossi, K. Dallaglio, E. Principi, A. Grimaldi, M. De Eguileor (Italy)
- Overcoming ARV-7-driven enzalutamide resistance by docetaxel in prostate cancer cell lines** 649
S. Garcia-Recio, M. Marin-Aguilera, N. Jiménez, O. Reig, P. Gascon, A. Prat, B. Mellado (Spain)
- Plumbagin, a medicinal plant derived naphthoquinone, may restore the efficacy and reduce intolerable toxicity of prostate anticancer drug docetaxel** 650
B. Hafeez, A.S. Anupma Singh, A. Verma (USA)
- γ -mangostin inhibits the proliferation of breast cancer cells by targeting AKR1B10** 651
D. Luo, X. Peng, Y. Guo, L. Huang (China)
- Androgen receptor variant 7 as a prognostic biomarker to docetaxel response in metastatic castration resistant prostate cancer** 652
M. Marin-Aguilera, O. Reig, G. Carrera, N. Jiménez, S. Garcia-Recio, P. Gascón, A. Prat, B. Mellado (Spain)
- Involvement of the proto-oncogene merrk receptor tyrosine kinase in the hepatic fibrogenic process** 653
G. Di Maira, S. Petta, A. Cappon, E. Vivoli, V. Di Marco, F. Marra (Italy)

ABSTRACT NR.	ABSTRACT NR.
Acquired resistance to vemurafenib in BRAF V600E mutant melanoma: BRAF translocations and rapid clonal dynamics <u>J. Mehnert</u> , A. Kulkarni, M. Yao, S. Pine, K. Hirshfield, S. Ali, L. Rodriguez, S. Ganesan (USA)	654 724
Development of diffuse intrinsic pontine glioma preclinical models at Hospital Sant Joan de Deu Barcelona <u>A.M. Carcaboso</u> , N.G. Olaciregui, S. Paco, J. Mora (Spain)	655 725
Activity of dasatinib in a patient-derived xenograft of alveolar rhabdomyosarcoma <u>G. Pascual-Pasto</u> , J. Mora, A.M. Carcaboso (Spain)	656 726
Targeting oncogenic pathways and HIF-1 α in colon tumors by combination of irinotecan and mTOR inhibitors of new generation <u>D. Reita</u> , M.P. Gaub, D. Guenot, E. Guerin (France)	657 727
MCT1 is crucial in metabolic adaptation of uterine cervix carcinomas to microenvironment - driven by STAT3:FOXM1 L.S. Silva, L.G. Goncalves, F. Silva, G. Domingues, R. Bordeira-Carriço, V. Maximo, J. Ferreira, E.W. Lam, A. Felix, <u>J. Serpa</u> (Portugal)	658 728
In vitro study of CNS metastasis in human acute lymphoblastic leukemia cell line <u>J. Sousa</u> (Portugal)	660 730
Cholangiocarcinoma (CCA) express chemokine receptor CXCR7: Important role of CXCR7 in mediating CXCL12 induced CCA cells chemotaxis and survival A. Gentilini, K. Rombouts, M. Pinzani, A. Caligiuri, C. Raggi, P. Invernizzi, C. Raschioni, <u>F. Marra</u> (Italy)	661 731
A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer <u>J. Moon</u> , J.S. Shin, S.A. Jung, S.W. Hong, J. Kim, S.H. Ha, E.K. Choi, H. Maureen, D.H. Jin, T.W. Kim (Korea)	662 732
ACORE-F serves as a response marker for the treatment of human hepatocellular carcinoma (HCC) with a MET inhibitor <u>J. Shin</u> , J. Moon, S.A. Jung, E.K. Choi, S.W. Hong, S.M. Kim, J. Kim, D.H. Lee, D.H. Jin, T.W. Kim (Korea)	663 733
Ovarian cancer cells are auxotrophic for arginine and sensitive to human recombinant arginase I [HuArgI(Co)-PEG5000]-induced arginine depletion M. Reda, A. Bekdash, A.E. Frankel, <u>R. Abi-Habib</u> (Lebanon)	664 734
Tumour Immunology I	
xCT: A new cancer stem cell immunotherapeutic target for breast cancer <u>M. Macagno</u> , S. Lanzardo, L. Conti, R. Ruiu, R. Calogero, F. Cavallo (Italy)	718 738
Tumor-infiltrating lymphocytes and cancer associated fibroblasts crosstalk in prostate cancer progression <u>G. Comito</u> , L. Lombardelli, F. Logiodice, O. Kulloli, E. Niccolai, A. Amedi, M.P. Piccinni, E. Giannoni, P. Chiarugi (Italy)	719 739
Norepinephrine establishes immunosuppressive network in human melanoma microenvironment <u>M. Calvani</u> , M. Becatti, A. Casini, C. Azzari, L. Filippi, P. Chiarugi (Italy)	720 740
The pro angiogenic phenotype and function of tumor infiltrating (TINKs) and tumor associated (TANKs) Natural Killer cells in colorectal-cancer <u>A. Bruno</u> , S. Zanellato, L. Dominion, L. Boni, E. Cassinotti, G. David, E. Zanetti, L. Mortara, A. Albini, D. Noonan (Italy)	721 741
Cancer immunotherapy diagnostic panel <u>A. Chenchik</u> , C. Frangou, L. Iakoubov (USA)	722 742
Efficacy of a cancer vaccine against ALK-rearranged lung tumors C. Voena, M. Menotti, C. Mastini, D.L. Longo, M.E. Boggio Merlo, C. Ambrogio, V.G. Minerò, G. Inghirami, P.A. Janne, <u>R. Chiarle</u> (USA)	723 743
Mutated variant of HER2 as a target for immunotherapy in breast cancer <u>S. Occhipinti</u> , C. Angelini, D. Pierobon, A. Amici, C. Marchini, S. Bustreo, M. Donadio, C. Marchiò, F. Novelli, M. Giovarelli (Italy)	724 744
Novel anti-tumor effects of Dkk1 neutralization via targeting β -catenin in myeloid suppressor cells <u>R. Faccio</u> (USA)	725 745
Characterisation of novel selective and dual-acting inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) for the treatment of cancer A. Wise, P.M. Cowley, <u>B.E. McGuinness</u> , S.C. Trewick, N.J. Bevan, C.L. Szybut, T.J. Brown (United Kingdom)	726 746
MONDAY 22 JUNE 2015	
Cancer Genomics, Epigenetics and Genome Instability II	
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability <u>C. An</u> , J. Lee, Y. Choi, H. Oh, M. Choi, M. Gwak, Y. Chung, N. Yoo, S. Lee (Korea)	119 747
CpG island methylation profiling in bortezomib-treated multidrug-resistant cancer cell line <u>K.Y. Chong</u> , T.H. Hung, C.J. Shen, C.M. Chen (Taiwan)	120 748
A combination of expression biomarkers PSA, PCA3 and AMACR in urine outperforms the PSA test alone in diagnostics of prostate cancer <u>D. Kachakova</u> , A. Mitkova, I. Popov, E. Popov, A. Vlahova, T. Dikov, S. Christova, C. Slavov, V. Mitev, R. Kaneva (Bulgaria)	122 750
The histone methyltransferase EHMT2/G9a epigenetically activates BECN1 to control of autophagy <u>S. Park</u> , H.J. Yi, J.J. Hwang (South Korea)	123 751
Bioinformatic approaches for somatic mutation calling, annotation and selection in in matched sensitive-resistant ovarian tumor pairs <u>L. Beltrame</u> , L. Paracchini, L. Clivio, B.A. Chapman, E. Calura, C. Romualdi, I. Craparotta, M. D'Incalci, S. Marchini (Italy)	124 752
High MALAT 1 expression induce metastasis process in early stage colorectal cancer patients <u>S. Ak</u> , B. Tunca, G. Tezcan, G. Cecener, U. Egeli, T. Yilmazlar, E. Ozturk, O. Yerci (Turkey)	125 753
Genetic variations in miRNA-binding sites of KRAS related with invasion in Turkish Pancreatic Cancer patients <u>S. Ak</u> , G. Cecener, U. Egeli, E. Demirdogen, B. Tunca, E. Kaya, O. Yerci (Turkey)	126 754
Down-expression of miR-152 and miR-212 in leiomyosarcoma and undifferentiated pleomorphic sarcoma C. Novello, <u>L. Pazzaglia</u> , I. Quattrini, S. Pollino, A. Conti, M.S. Benassi (Italy)	127 755
Exome sequencing in primary melanoma provides insights into genetic alterations associated with melanoma progression <u>V. Montagnani</u> , M. Benelli, A. Apollo, S. Pandolfi, G. Gerlini, L. Borgognoni, B. Stecca (Italy)	128 756
The down-modulation of miR-23b in human hepatocellular carcinoma is mediated by DNA methylation <u>L. Grossi</u> , A. Salvi, B. Arici, N. Portolani, G. De Petro (Italy)	129 757
Next Generation Sequencing (NGS) approach to investigate new mutations in pediatric Glioblastoma Multiforme <u>L. Giunti</u> , A. Provenzano, R. Artuso, B. Mazinghi, M. Da Ros, A.L. Iorio, A.M. Buccoliero, F. Castiglione, S. Giglio, I. Sardi (Italy)	130 758
Epigenetic therapy in retinoblastoma tumor: From computational system biology to pre-clinical models M. Taranta, I. Naldi, <u>L. Gherardini</u> , F. Malusa, E. Capobianco, C. Cinti (Italy)	131 759

	ABSTRACT NR.		ABSTRACT NR.
Interstitial deletion of chromosome 5q in a patient with Familial Adenomatous Polyposis and mild developmental delay <i>T. Kadiyska, A. Todorova, A. Chavushian, A. Petrov (Bulgaria)</i>	132	Effects of phosphatidylcholine-specific phospholipase C inhibition on tumour growth, metabolism and HER2 expression in preclinical models of HER-2 overexpressing ovarian cancer <i>R. Canese, L. Paris, A. Ricci, M.E. Pisanu, L. Altabella, M. Bagnoli, L. Liliac, D. Mezzanzanica, E. Iorio, F. Podo (Italy)</i>	259
miRNA landscape analysis in patients with high grade serous advanced ovarian cancer receiving neoadjuvant chemotherapy <i>S. Marchini, M. Petrillo, C. Romualdi, L. Beltrame, E. Martinelli, A. DiFeo, C. Nero, M. D'Incalci, G. Scambia, G. Zannoni (Italy)</i>	133	The interaction between CD157 and fibronectin modulates acute myeloid leukemia cell behavior <i>S. Augeri, S. Morone, M. Cuccioloni, M. Mozzicafreddo, N. Lo Buono, S. Dardia, S. Aydin, E. Ortolan, A. Funaro (Italy)</i>	260
The long non-coding RNA HOTAIR is aberrantly down-regulated in alveolar fusion-positive rhabdomyosarcoma <i>R. Rota, B. Conti, M. Colletti, S. Vella, P.P. Leoncini, J. Roma, S. Gallego, R.S. Redis, G. Calin, F. Locatelli (Italy)</i>	134	Fibroblast role in the acquisition and maintenance of anti-Her2 target therapies resistance in breast cancer <i>P. Fernandez, G. Fuster, M. Mancino, E. Enreig, E. Ametller, P. Bragado, V. Almendro, P. Gascon (Spain)</i>	261
An integrated approach for the study of colorectal cancer: From methylome to transcriptome <i>P. Zavattari, L. Moi, D. Gentilini, C. Zavattari, A. Fadda, V.P. Leoni, P. Sulas, L. Zorcolo, L. Varesco, A. Columbano (Italy)</i>	135	A novel function of Bcl-2 protein: miR-211 regulation in melanoma cells <i>T. De Luca, A. Pelosi, D. Trisciuglio, S. D'Aguianno, T. Battisti, M.G. Rizzo, D. Del Bufalo (Italy)</i>	262
Elucidating the role of SGK3 in driving poor prognosis in cancer <i>K.A. Menezes, P. Cunnea, P. Lawton, E. Curry, H. Gabra, H. Wasan, S.K. Sharma, E.A. Stronach (United Kingdom)</i>	136	Metabolic and proteomic characterization define two different groups of glioblastoma stem-like cells <i>M. Buccarelli, G. Marziali, M. Signore, S. Grande, A. Palma, M. Biffoni, R. Pallini, L. Ricci-Vitiani (Italy)</i>	263
Epigenetic biomarker exploration in 5-fluorouracil response against colorectal cancer <i>I. Hwang, Y. Choi, H. Jung, D. Seo, Y. Hyun, J. Lee, H. Nah, J. Kim (Korea)</i>	137	Establishment and characterization of a human metastatic melanoma cell line under serum-low conditions <i>A. Del Pino-Zumaquero, G. Ligerio, P. Catalina, J.D. Rejon, I. Gutierrez-Aranda, J.A. Carrillo, A.M. Sanchez (Spain)</i>	264
Carcinogenesis II			
In utero exposure to lipotropic (methyl) nutrients suppresses mammary carcinogenesis in two generations of offspring <i>C. Park, K.B. Cho, L. Mabasa, W.S. Choi, C.L. Crane, M.R. Almeida (USA)</i>	146	A therapeutic approach for Cu(II) complex, [Cu ₂ (μ-(C ₆ H ₅) ₂ CHCOO) ₃ (bipy) ₂](ClO ₄): The potential cytotoxic and apoptotic effects of developed SLNs formulation as drug delivery system <i>G. Guney Eskiler, G. Cecener, I. Kani, G. Dikmen, B. Tunca, U. Egeli (Turkey)</i>	265
The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro <i>O. Piskareva, J. Nolan, H. Harvey, R. Conlon, F. O'Sullivan, P. Dowling, I. Bray, R.L. Stallings (Ireland)</i>	147	Establishment of a program of cytogenetic cell lines control derived and deposited in a biobank for potential clinical use and research <i>P. Catalina, G. Ligerio, A. Del Pino-zumaquero, B. Miranda (Spain)</i>	266
Neurofilament (NEF-L) is overexpressed in human and rodent HCC and predicts recurrence in HCC patients <i>C. Puggioni, C. Manca, R. Loi, A. Perra, V.P. Leoni, A. Petrelli, L. Gramantieri, F. Fornari, S. Giordano, A. Columbano (Italy)</i>	148	Endothelin A receptor drives invadopodia function and cell motility through β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma <i>E. Semprucci, P. Tocci, R. Cianfrocca, M. Vegliione, R. Sestito, V. Di Castro, G. Ferrandina, A. Bagnato, L. Rosanò (Italy)</i>	267
Improvement of tumor photoacoustic molecular images by unmixing <i>P. Giustetto, V. Lorusso (Italy)</i>	149	Cellular activity of microRNAs dysregulated in breast cancer <i>C. Zerbinati, F. Corrà, L. Minotti, M. Galasso, F. Ferri, M. Prevati, S. Volinia (Italy)</i>	269
p53 independent G1 arrest accompanied by DNA damage and apoptosis induced by dietary flavonoid fisetin in human gastric cancer cells <i>A. Sabarwal, R. Agarwal, R.P. Singh (India)</i>	150	Autocrine Activation of HGF/c-Met signaling mediates acquired resistance to sorafenib in HCC cells <i>Z. Firtina Karagonlar, D. Koc, E. O. Iscan, S.E. Erdal, S.N. Atabay (Turkey)</i>	270
The IMP3-PDPN axis is associated with bone invasion and prognosis in oral squamous cell carcinoma <i>X. Zhang, J.Y. Bae (Korea)</i>	151	Deep sequencing of glioblastoma tissues and peritumoral regions reveals mRNAs and microRNAs depicting molecular pathways shared by tumors and surrounding areas and highlights differences between short-term and long-term survivors <i>B. Fazi, A. Felsani, L. Grassi, A. Guffanti, D. D'Andrea, N. Toschi, D. Sicari, M.G. Farace, A. Mangiola, S. Ciafre' (Italy)</i>	271
Pyruvate dehydrogenase kinase 1 (PDHK1) regulates ovarian cancer cell migration, invasion, and chemoresistance and contributes to poor prognosis in patients <i>Y. Jiang, M. Siu, A. Cheung, H. Ngan, K. Chan (Hong Kong)</i>	152	Anti-apoptotic effects of lentiviral vector transduction promote Rituximab Tolerance in cancerous B cells <i>B. Ranjbar, M.B. Laursen, S.C. Marques, K. Dybkær, J.G. Mikkelsen (Denmark)</i>	272
Cell and Tumour Biology II			
Investigate the role of Sialyltransferase inhibitor on MDA-MB231 breast cancer cells in vitro and in vivo <i>H. Tsai, C.W. Fu, T.T. Chang, C.L. Chen, W.S. Li (Taiwan)</i>	256	A N-truncated isoform of the orphan nuclear receptor COUP-TFII modulates pancreatic cancer progression <i>S. Polvani, S. Tempesti, M. Tarocchi, G. Marroncini, E. Ceni, T. Mello, M. Farsi, L. Bencini, I. Bartolini, A. Galli (Italy)</i>	273
L-2-hydroxy acid oxidase 2 (Hao2): A new oncosuppressor in hepatocellular carcinoma development? <i>S. Mattu, A. Perra, A. Petrelli, L. Gramantieri, F. Fornari, G.M. Ledda-Columbano, L. Terracciano, L. Quagliata, S. Giordano, A. Columbano (Italy)</i>	257		

	ABSTRACT NR.		ABSTRACT NR.
All-trans retinoic acid modulates epithelial to mesenchymal transition and inhibits cell motility in ERBB2/RARA amplified breast cancer cells: Role of NOTCH1 and TGFβ pathways <u>G. Paroni</u> , A. Zanetti, R. Affatato, F. Centritto, M. Fratelli, M. Kurosaki, E. Garattini (Italy)	274	Characterization of a mantle cell lymphoma cell line resistant to a Chk1 inhibitor V. Restelli, R. Chilà, M. Lupi, F. Bertoni, G. Damia, <u>L. Carrassa</u> (Italy)	294
The effect of metformin on the proliferation of H295R cell line <u>R. Armignacco</u> , G. Poli, G. Cantini, L. Canu, M. Mannelli, M. Luconi (Italy)	275	XMD8-92, an ERK5 inhibitor, in combination with imatinib, as a useful approach for CML treatment and prevention of relapse <u>I. Tusa</u> , G. Cheloni, N. Grey, X. Deng, A. Gozzini, E. Rovida, P. Dello Sbarba (Italy)	295
Identification of cisplatin-resistance related genes in ovarian clear cell carcinoma using 3D cell culture system <u>I.J. Liu</u> , H.Y.S. Ngan, D.W. Chan (Hong Kong)	276	Exploiting the hERG1/β1/PI3K complex to overcome anti-angiogenesis therapy resistance in gastrointestinal cancers <u>O. Crociani</u> , S. Pillozzi, M. Stefanini, E. Lastraioli, G. Bartoli, C. Duranti, S.S. Manoli, N. Kuppala, A. Arcangeli (Italy)	296
Role of miR-1247 in prostate cancer progression <u>L. Cavallini</u> , M.L. Taddei, L. Ippolito, P. Gandellini, E. Giannoni, P. Chiarugi (Italy)	277	Epithelial ovarian cancer: Affecting tumor aggressiveness and drug sensitivity by targeting aberrant metabolism A. Granata, R. Nicoletti, P. Perego, E. Iorio, B. Krishnamachary, F. Benigni, A. Ricci, Z.B. Bhujwala, <u>M. Bagnoli</u> , D. Mezzanzanica (Italy)	297
Molecular differences between 1,25-dihydroxyvitamin D3-sensitive and -resistant acute myeloid leukemia cells <u>E. Gocek</u> , E. Marcinkowska (Poland)	279	Proteomic analysis of SHH Medulloblastoma stem-like cells <u>G. Catanzaro</u> , M. Ronci, V. Alfano, Z.M. Besharat, L. Aballe, L. Pieroni, I. Screpanti, A. Urbani, E. Ferretti (Italy)	300
Sirtuins as metabolic sensors of tumor: Stroma crosstalk <u>L. Ippolito</u> , E. Giannoni, M.L. Taddei, P. Chiarugi (Italy)	280	The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style <u>A. Chilà</u> , F. Margheri, C. Luciani, M.L. Taddei, E. Giannoni, A. Laurenzana, A. Biagioni, P. Chiarugi, G. Fibbi, M. Del Rosso (Italy)	301
A novel role of phosphatidylcholine-specific phospholipase C in modulating CXCR4 chemokine receptor in human glioblastoma cells <u>L. Mercurio</u> , S. Cecchetti, A. Ricci, G. Cigliana, F. Podo, G. Carpinelli, E. Iorio (Italy)	281	PDGF-D maintains tumor cell heterogeneity in an experimental model of pancreatic neuroendocrine tumors <u>E. Cortez</u> , H. Gladh, E. Folestad, S. Braun, E. Cordero, U. Eriksson, K. Pietras (Sweden)	302
Feasibility of a workflow for the molecular characterization of single circulating tumor cells by next generation sequencing F. Salvianti, G. Rotunno, F. Galardi, F. De Luca, M. Pestrin, A.M. Vannucchi, A. Di Leo, M. Pazzagli, <u>P. Pinzani</u> (Italy)	283	Selective agonists for M2 muscarinic receptors inhibit cell proliferation and survival in human glioblastoma cells: Possible implications in drug resistance <u>I. Cristofaro</u> , M. Di Bari, R. Fanfarillo, Z. Spinello, C. Matera, M. De Amici, C. Dallanocce, L. Conti, A.M. Tata (Italy)	303
Pro-inflammatory cytokines and chemokines analysis in HPV-positive cancer cells <u>G. Mangino</u> , M.S. Zangrillo, M.V. Chiantore, M. Iuliano, R. Accardi, G. Fiorucci, M. Tommasino, G. Romeo (Italy)	284	Significance of CDKN1B driver mutations in the growth and response to therapy of Luminal BC <u>M. Cusan</u> , I. Segatto, S. D'andrea, S. Benevol, B. Belletti, G. Baldassarre (Italy)	304
MMP2 as a molecular biomarker of stromal priming in lung cancer E. Baldoli, T. Caputo, <u>F. Andriani</u> , F. Facchinetti, M. Moro, U. Pastorino, G. Sozzi, G. Sozzi, L. Roz (Italy)	285	Therapeutic potential of metformin and phenformin in targeting the stem cell compartment in malignant melanoma <u>K. Dallaglio</u> , T. Petrachi, M. Chiappelli, C. Bonelli, D.M. Noonan, A. Albini (Italy)	305
Novel 1,2,3-triazolium salts obtained via click chemistry – potential anticancer agents <u>I. Steiner</u> , N. Stojanovic, A. Bolje, A. Ambriovic-Ristov, A. Brozovic, M. Radic Stojkovic, I. Piantanida, D. Eljuga, J. Kosmrlj, M. Osmak (Croatia)	286	PI3KC2a, a new spindle associated protein involved in genomic instability and tumorigenesis <u>M.C. De Santis</u> , M. Martini, F. Gulluni, A. Ghigo, J.P. Margaria, C.C. Campa, E. Ciraolo, A. Sapino, R. Chiarle, E. Hirsch (Italy)	306
Early onset of the adaptive response to drugs in colon cancer: Novel players and potential biomarkers <u>E. Enreig Cabanes</u> , M. Mancino, P. Fernandez, V. Almendro, F.J. Casado, P. Gascón, E. Ametller, C. Nadal, N. Carbó (Spain)	288	p140Cap, a Chromosome 17q12-q21 scaffold protein, is a new prognostic marker in ERBB2 breast cancer S. Grasso, I. Castellano, K. Dallaglio, A. Albini, J. Staaf, P.P. Di Fiore, G. Bertalot, M. Confalonieri, E. Turco, <u>P. Defilippi</u> (Italy)	307
Melanoma inhibitors and microrna <u>L. Minotti</u> , M. Galasso, F. Corrà, C. Zerbinati, F. Ferri, M. Fassan, M. Previati, S. Volinia (Italy)	289	Infantile myofibromatosis PDGFRB mutants are constitutively activated and sensitive to tyrosine kinase inhibitors F.A. Arts, D. Chand, B. Hallberg, <u>J.B. Demoulin</u> (Belgium)	308
Inhibition of uPAR-TGFβ cross-talk blocks MSC-dependent EMT in melanoma cells <u>A. Laurenzana</u> , A. Biagioni, F. Bianchini, S. Peppicelli, A. Chilà, F. Margheri, N. Pimpinelli, M. Del Rosso, L. Calorini, G. Fibbi (Italy)	290	Role of miRNA-214 in melanoma progression <u>D. Dettori</u> , F. Orso, E. Penna, L. Salmena, P.P. Pandolfi, D. Taverna (Italy)	309
A KRAS and dual concomitant PI3KCA mutations in a metastatic colorectal cancer patient with aggressive and resistant disease <u>A. Tessitore</u> , G. Bruera, V. Mastroiaco, K. Cannita, A. Cortellini, D. Di Giacomo, F. Zazzeroni, C. Ficorella, E. Ricevuto, E. Alesse (Italy)	291	Monocytes/macrophages in cancer, from tumor aggressors to vascular components - a new insight for anti-angiogenic therapy G. Domingues, S. Gouveia-Fernandes, D. Salgado, S. Nunes, S.A. Pereira, F. Coelho, F. Silva, A. Félix, <u>J. Serpa</u> (Portugal)	310
ID4-driven cross-talk between breast cancer cells and tumor-associated macrophages S. Donzelli, E. Milano, I. Iosue, E. Melucci, E. Gallo, I. Terrenato, M. Mottotese, G. Blandino, F. Fazi, <u>G. Fontemaggi</u> (Italy)	292	BM-MSc loaded with PTX home to brain tumor and induce cytotoxic damage <u>S. Pacioni</u> , M.L. Falchetti, A. Pessina, V. Cocce', G. Alessandri, L. Pascucci, S. Giannetti, R. Pallini (Italy)	311
Understanding the role of Cyclophilin A during cytokinesis: a novel role for the NEK kinase family P.M. Lavin, K. Brennan, <u>M.M. Mc Gee</u> (Ireland)	293		

	ABSTRACT NR.		ABSTRACT NR.
Pharmacological characterisation of nicotinic receptors in gliomas and glioblastoma cells <u>F. Fasoli</u> (Italy)	312	The effects of nicotine in non small cell lung cancers by binding neuronal nicotinic acetylcholine receptors <u>V. Mucchietto</u> (Italy)	327
CXCR4 deregulation in Notch3-induced acute T cell lymphoblastic leukemia <u>F. Ferrandino</u> , G. Bernardini, P. Grazioli, A.F. Campese, R. Palermo, A. Ciuffetta, D. Bellavia, I. Screpanti, M.P. Felli (Italy)	313	Use of a perfusion-based bioreactor to maintain in vitro the tumor microenvironment of primary human colorectal cancer specimens C. Manfredonia, C. Hirt, V. Mele, F. Amicarella, R. Droeser, G.C. Spagnoli, I. Martin, A. Papadimitropoulos, G. Iezzi, <u>M.G. Muraro</u> (Switzerland)	328
Metabolomic profile of biological fluids of ovarian cancer patients <u>J. Sousa</u> , G. Graca, F. Silva, F. Coelho, M. Silveira, A. Guimarães, P. Simoes, J. Serpa, A. Felix, L. Gonçalves (Portugal)	314	The role of Nek 6 gene expression in multidrug resistance and apoptosis in MCF-7 and K-562 cell lines <u>A. NABIOLU</u> , P. Mutlu, S. Yalcin, U. Gündüz (Turkey)	329
BMP2 promotes doxorubicin-resistance in breast cancer cells <u>A. Hermawan</u> , F. Kopp, J. Busse, A. Herrmann, J. Garcia-Roman, E. Wagner, A. Roidl (Germany)	315	Modulation of Acute Myeloid Leukemia (AML) metabolism by the Vascular Endothelial Growth Factor (VEGF) - in vitro study C. Nunes, F. Brito, L.G. Goncalves, G. Graca, <u>F. Coelho</u> , F. Silva, M.G. Silva, J. Cabecadas, J. Serpa (Portugal)	330
Identification and characterization of a novel ARID1a interaction with CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase) S. Mi, M. Schwartz, <u>G. Huang</u> (USA)	316	Role of WNT/ β -Catenin pathway in endocannabinoid-mediated antitumor effects in human CRC <u>D. Fiore</u> , M.C. Proto, A.C. Pagano Zottola, S. Pisanti, E. Ciaglia, M. Bifulco, P. Gazzero (Italy)	332
Differential uPAR recruitment in caveolar-lipid rafts by gm1 and gm3 gangliosides regulates endothelial progenitor cells angiogenesis <u>F. Margheri</u> , L. Papucci, N. Schiavone, A. Laurenzana, C. Luciani, A. Chillà, T. Del Rosso, G. Margheri, M. Del Rosso, G. Fibbi (Italy)	317	Antiproliferative effect of N(6)-isopentenyladenosine in human colorectal cancer cell lines: New potential role in epigenetic regulation M.C. Proto, <u>D. Fiore</u> , A.C. Pagano Zottola, M. Vasaturo, S. Pisanti, E. Ciaglia, F. Dal Piaz, M. Bifulco, P. Gazzero (Italy)	333
Loss of Class II PI3K-C2A promotes aneuploidy in breast cancer and sensitivity to anti-mitotic agents <u>M. Martini</u> , F. Gulluni, M.C. De Santis, A. Ghigo, E. Ciraolo, J.P. Margaria, C.C. Campa, A. Sapino, R. Chiarle, E. Hirsch (Italy)	318	SGK2: A new modulator of platinum drug resistance in epithelial ovarian cancer <u>V. Ranzuglia</u> , A. Dall'Acqua, M. Sonogo, I. Pellizzari, B. Belletti, G. Baldassarre, M. Schiappacassi (Italy)	334
Concomitant intracellular retention of SPARC and CATHEPSIN B by SCD5-induced oleic acid production reduces melanoma malignancy R. Puglisi, M. Bellenghi, F. Pedini, A. De Feo, S. Sangaletti, M.C. Errico, C. Tripodo, M.P. Colombo, <u>G. Mattia</u> , A. Carè (Italy)	319	Characterization of a murine orthotopic xenograft model of glioblastoma multiforme: The glioma stem cell gamble <u>G. Riva</u> , A. Salvaggio, G. Romano, A. Trezza, C. Giussani, R. Giovannoni, A. Bentivegna (Italy)	335
Tumor-associated stromal cells increase malignancy of human colorectal cancer inducing epithelial-to-mesenchymal transition <u>V. Mele</u> , M.G. Muraro, R. Droeser, D. Oertli, M. Zuber, R. Rosso, I. Martin, M. Heberer, G.C. Spagnoli, G. Iezzi (Switzerland)	320	Validation of let-7c cluster as breast carcinoma early biomarkers using a bioluminescent mouse model T. Battisti, I. Manni, L. De Latouliere, G. Piaggio, M.G. Rizzo, <u>F. Russo</u> (Italy)	336
Nrf2, but not β -catenin, mutation represents an early event in rat hepatocarcinogenesis <u>S. Menegon</u> , P. Zavattari, A. Perra, M.M. Angioni, A. Petrelli, L. Quagliata, G.M. Ledda-columbano, L. Terracciano, S. Giordano, A. Columbano (Italy)	321	Chemopreventive activity of olive mill wastewaters <u>T. Rossi</u> , A. Bruno, B. Bassani, S. Canali, C. Gallo, A. Albini (Italy)	337
Inhibition of CXCR4 receptor by a novel peptide antagonist modulates microglia reactivity and angiogenesis in a human glioblastoma model <u>L. Mercurio</u> , M.A. Ajmone-Cat, S. Cecchetti, A. Ricci, L. Portella, S. Scala, L. Minghetti, G. Carpinelli (Italy)	322	Roles and mechanisms of NANOG-mediated drug resistance in human colorectal cancer cells <u>S. Shaheen</u> , R. Babaei-Jadidi, A.S. Nateri (United Kingdom)	338
Ovarian cancer peritoneal dissemination is characterized by a loss of miR-506 expression associated to acquisition of mesenchymal phenotype and increased resistance to platinum treatment M. Bagnoli, L. De Cecco, R. Nicoletti, A. Cacciamali, M.L. Carcangiu, F. Galdiero, G. Scognamiglio, W. Zhang, S. Pignata, <u>D. Mezzanzanica</u> (Italy)	323	Development of a novel tumor homing compound with antiproliferative and anti-metastatic profile for glioblastoma multiform <u>K.E. Siatis</u> , A. Lampropoulou, E. Giannopoulou, C. Papadopoulos, S. Papis, E. Briasoulis, A. Tzakos, V. Tsikaris, H.P. Kalofonos (Greece)	339
Phospholipid scramblase 1: At the cross-road between autophagy and apoptosis in mantle cell lymphoma <u>B. Montico</u> , K. Mastorci, L. Sigalotti, D.A. Faè, M. Doglioni, R. Dolcetti, J. Dal Col (Italy)	324	Vorinostat induces HNF1 β expression and latency in ovarian clear cell carcinoma (OCCC) and resistance in ovarian serous carcinoma (OSC) F. Silva, F. Coelho, S. Fernandes, A. Félix, <u>J. Serpa</u> (Portugal)	340
miR-199a-3p in vivo study in papillary thyroid carcinoma mouse model <u>E. Minna</u> , P. Romeo, L. Cleris, V. Mauro, S. Pilotti, M.G. Rizzetti, G. Manenti, A. Greco, M.G. Borrello (Italy)	325	Diverse role of mesenchymal stromal cells in tumor biology <u>S. Skolekova</u> , L. Kucerova (Slovak Republic)	341
Identification of chromosomal alterations in different breast cancer subpopulations reveals distinctive molecular profiles and therapeutic responses M. Montanari, A. Conti, R. Genesio, R. Cicatiello, <u>L. Coppola</u> , M.R. Carbone, C. Di Mauro, R. Bianco, S. De Placido, B.M. Veneziani (Italy)	326	Immodin and its effect on 4T1 derived mouse breast cancer in vivo when combined with Paclitaxel or Manumycin A <u>P. Solár</u> , V. Sacková, M. Kassayová, B. Bojková, V. Demecková, G. Hrková, R. Jendželovský, D. Mudronová, S. Gancarcíková, P. Fedorocko (Slovak Republic)	342
		Characterization of non-competitive inhibitors of androgen receptor identified from high throughput screening <u>L. Sun</u> , H. Bouamar, J. Deng, J. Yang, L. Xia (USA)	343
		M2 receptor activation inhibits cell growth and survival in human breast cancer A. Espanol, M. Di Bari, I. Cristofaro, M.E. Sales, <u>A.M. Tata</u> (Italy)	344

	ABSTRACT NR.		ABSTRACT NR.
The role of apoptosis regulator programmed cell death 10 (PDCD10) in multidrug resistance <u>C. Urfali-Mamatoglu</u> , U. Gunduz (Turkey)	345	Small activating RNAs activate DPYSL3 gene expression in prostate cancer cells <u>B. Li</u> , C. Li, W. Jiang, J.B. Thrasher (USA)	456
Inhibition of PDGFR β signaling reduces glioblastoma progression due to BM-MSCs recruitment <u>R. Fontanella</u> , S. Camorani, L. Cerchia, A. Zannetti (Italy)	346	Apoptotic pathway of zinc on cervical cancer cell line <u>K. Lee</u> , S.N. Bae (Korea)	458
Bone marrow-derived mesenchymal stem cells drive epithelial- mesenchymal transition in osteosarcoma cells through CXCL12/CXCR4 <u>R. Fontanella</u> , A. Pelagalli, S. Scala, L. Auletta, R. Palumbo, A. Zannetti (Italy)	347	Blockade of SDF-1/CXCR4 axis is additive/synergistic with radiotherapy and/or temozolomide treatment both in vitro and in vivo in preclinical models of glioblastoma G. Gravina, A. Mancini, A. Colapietro, A. Jitariuc, S. Delle Monache, E. Di Cesare, P.J. Richardson, L. Patient, S. Burbidge, <u>C. Festuccia</u> (Italy)	459
Angiogenic switch in prostate cancer: PGE2 and miRNA regulation E. Terzuoli, F. Finetti, A. Giachetti, <u>S. Donnini</u> , M. Ziche (Italy)	348	Investigation of the anti-tumor activity of a new synthetic n-tosyl-aza-pterocarpan LQB-223 in breast cancer cells L.G.T.L. Lemos, G.N.M. Nestal de Moraes, D.D. Delbue, F.C.V. Vasconcelos, P.S.B. Bernardo, M.X.G.P. Pereira, C.D.B. Buarque, E.W.F.L. Lam, P.R.R.C. Costa, <u>R. Maia</u> (Brazil)	460
Exosome-mediated transfer of miR-222 promotes tumor progression of melanoma A. De Feo, C. Coscia, G. Mattia, F. Felicetti, <u>A. Care</u> (Italy)	349	Identification of genes involved in triple-negative breast cancer sensitivity and resistance to paclitaxel using an in vivo total genome knockdown screen <u>M. Sultan</u> , M.L. Thomas, K.M. Coyle, T.T. Huynh, C.A. Giacomantonio, P. Marcato (Canada)	461
Study of mitochondrial energy metabolism in the sensitivity of breast cancer cells to anthracyclines and in their chemosensitization by n-3 polyunsaturated fatty acids <u>J. Dartier</u> , K.M. Maheo, E.L. Lemaitre, M.P. Pinault, S.C.H. Chevalier, C.G. Goupille, S.S. Servais, J.F.D. Dumas (France)	350	The MUC4 oncomucin mediates human pancreatic cancer cell resistance to 5-fluoro-uracil and oxaliplatin chemotherapeutic drugs N. Skrypek, L. Kotzmann, R. Vasseur, F. Lahdaoui, B. Duchêne, <u>I. Van Seuning</u> , N. Jonckheere (France)	462
Interplay between p53 and miR-34a in T-cells transformed by HTLV-1 <u>D. D'Agostino</u> , V.K. Sharma, V. Raimondi, M. Silic-Benussi, I. Cavallari, V. Ciminale (Italy)	351	Organic Cation Transporter-1 (OCT1) dependent and independent mechanisms of sorafenib resistance in human hepatocellular carcinomas <u>S. Dash</u> , S. Chava, P.K. Chandra, R. Panigrahi, P.K. Ferraris, J. Liu, H. Chang, J. Buell, J.J. Marin (USA)	466
Nck2 pathways promote aggressiveness and angiogenesis in ovarian cancer M. Fanelli, L. Petrella, <u>A. Camperchioli</u> , M. Petrillo, C. Baranello, P. Baccaro, C. Ferlini, G. Scambia (Italy)	352	Metformin inhibits the growth of human osteosarcoma xenografts by inducing cell cycle arrest in G0/G1 phase <u>J.A. Lee</u> , Y. Ko, M. Lee (Korea)	467
Identification and characterisation of pancreatic cancer stem cells <u>M. Acar</u> , K. Yildirim, E. Gunduz, M. Dogan, O.F. Hatipoglu (Turkey)	353	Oncogenic activity of HNF4alpha in gastric cancer: AMPK to WNT signaling in early-stage gastric cancer H.R. Chang, S. Nam, M.C. Kook, H.R. Jung, Y.W. Kim, D. Tan, G. Powis, T. Park, H. Liang, <u>Y. Kim</u> (Korea)	468
Experimental/Molecular Therapeutics, Pharmacogenesis II			
New insights into drug resistance phenotypes using a novel microdevice for high-throughput in vivo drug sensitivity testing <u>Q. Jonas</u> , R. Langer (USA)	448	A pathway-based approach: Identifying biomarkers of tumor progression to Trastuzumab-resistant breast cancer S. Nam, H.R. Chan, J. Lee, G. Powis, E.S. Lee, J. Ro, <u>Y. Kim</u> (Korea)	469
ABC B1 overexpression represents a novel mechanism for acquired resistance to polo-like kinase 1 inhibitors volasertib <u>C. Wu</u> , S.H. Hsiao, C.Y. Su, Y.Q. Li, Y.H. Huang (Taiwan)	449	Cardiac Glycosides induce cell death in drug resistant PTEN deficient liver cancer cells I. Durmaz, E.B. Guven, T. Ersahin, M. Ozturk, I. Calis, <u>R. Cetin-Atalay</u> (Turkey)	470
Functional cooperation of MYC and EGR1 elicits apoptosis by controlling NOXA and BIM transcription upon proteasome inhibition by bortezomib <u>M. Wirth</u> , N. Stojanovic, J. Christian, M.C. Paul, R.H. Stauber, R.M. Schmid, G. Häcker, O.H. Krämer, D. Saur, G. Schneider (Germany)	450	Proteomic quantification of drug transporters, metabolizing enzymes and cancer target MTH1 in cancer cell lines <u>F. Gaugaz</u> , C. Gröer, D. Busch, S. Oswald, J.R. Wisniewski, U. Warpman Berglund, T. Helleday, P. Baranczewski, P. Artursson (Sweden)	472
Ascochlorin attenuates chemoresistance and regulates the plasticity of doxorubicin induced EMT via modulation of NF-kB pathway in hepatocellular carcinoma <u>X. Dai</u> , K. Ahn, C. Kim, J. Shi, A. Kumar, L. Wang, B. Goh, J. Magae, K. Hui, G. Sethi (Singapore)	451	The FDA approved antiviral agent cidofovir inhibits metastasis of FGF2-driven, virus-independent tumors <u>S. Liekens</u> , S. Noppen, C. Tobia, M. Presta (Belgium)	473
Targeting mesenchymal-like triple negative breast cancers with the combination of FGFR and Src inhibition <u>I.S. Babina</u> , N.C. Turner (United Kingdom)	452	Dual targeting of murine melanoma model; antitumor and antiangiogenic effects of integrin targeted gene therapy <u>M. Bosnjak</u> , T. Dolinsek, M. Cemazar, S. Kranjc, M. Stimac, J. Zavrnsnik, U. Kamensek, C. Bouquet, B. Turk, G. Sersa (Slovenia)	476
Experimental studies on the selection of effective anticancer drugs in vitro for recurrent breast cancer patients with skeletal metastases <u>V. Protsenko</u> , A. Ilnitskiy, Y. Kudryavets (Ukraine)	454	Down-regulation of PTTG1 contributes to dabrafenib-induced inhibition of melanoma cell proliferation and invasiveness S. Caporali, E. Alvino, P.M. Lacal, M.G. Atzori, G.C. Antonini Cappellini, <u>S. D'Atri</u> (Italy)	477
Overexpression of ABCB1 or ABCG2 in cancer cells reduced the activity of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR and HER2 <u>C. Su</u> , S.H. Hsiao, S.Y. Luo, Y.Q. Li, Y.H. Huang, C.P. Wu (Taiwan)	455	A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells <u>A. De Luca</u> , G. Graziani, D. Rotili, A. Muzi, A. Mai, C. Leonetti, S. Artuso, E. Bonanno, L. Tentori, A.M. Caccuri (Italy)	478

ABSTRACT NR.

ABSTRACT NR.

- Nitrobenzoxadiazoles exert anti-melanoma activity modulating the MAPK/JNK signaling** 479
A. De Luca, D. Rotili, D. Carpanese, A. Mai, A. Rosato, G. Graziani, C. Leonetti, C. Geroni, L. Quintieri, A.M. Caccuri (Italy)
- Therapeutic potential of metformin in refractory osteosarcoma: Metformin inhibits the proliferation of cisplatin-resistant osteosarcoma cells, but does not increase their radiosensitivity** 480
Y. Ko, M. Lee, J. Lee (Korea)
- In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl₂(3-Hmpy)₂]** 481
S. Kranjc, S. Grabner, J. Scancar, G. Sersa, M. Cemazar (Slovenia)
- Identification of novel functional interactors of BRAFV600E through a genetic screening in yeast** 482
S. Lubrano, T. Cervelli, L. Comelli, A. Galli, L. Polisenio (Italy)
- The new alkylating histone-deacetylase inhibitor (HDACi) fusion molecule EDO-S101 shows significant MGMT expression independent antitumor activity in preclinical models of human glioblastoma and is synergistic with radiotherapy** 483
C. Festuccia, G.L. Gravina, A. Mancini, A. Colapietro, L. Scarsella, S. Delle Monache, Y. Chen, E. Di Cesare, T. Mehrling (Italy)
- PEA-15 protein influences cisplatin resistance by altering ERK localization in ovarian cancer cells** 484
S. Dilruba, X. Xie, N.T. Ueno, A.C. Schiedel, M. Michaelis, J. Cinatl jr, G.V. Kalayda (Germany)
- Tumor heterogeneity in EGFR-mutant non-small-cell lung cancer** 485
A.M. Rachiglio, M. Lambiase, F. Fenizia, A. Morabito, G. Rocco, D. Galetta, B. Vincenzi, E. Barletta, R. Franco, N. Normanno (Italy)
- Selection of a novel berberine derivative with antitumor efficacy on HER2 positive murine breast cancer** 486
P. Lombardi, F. Buzzetti, G. Fiorillo, C. Geroni, E. Pierpaoli, C. Plasencia, M. Provinciali, C. Salvatore, T. Monir Syeda (Italy)
- Studies on the co-expression of growth factor receptors in human breast tumour cells and their responses to treatment with various tyrosine kinase inhibitors** 487
A. Stanley, H. Ashrafi, A. Seddon, H. Modjtahedi (United Kingdom)
- Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer** 488
K. Dalal, M. Roshan-Moniri, A. Sharma, H. Li, F. Ban, M.D. Hassona, E. LeBlanc, E.S. Tomlinson-Guns, A. Cherkasov, P.S. Rennie (Canada)
- TERT inhibition leads to cell cycle alterations and increases the apoptotic effects of chemotherapeutic agents in EBV-immortalized B lymphocytes** 489
A. Celeghin, S. Giunco, R. Freguja, F. Argenton, A. De Rossi (Italy)
- Ranolazine inhibits Nav1.5-mediated breast cancer cell invasiveness and lung colonisation** 490
V. Driffort, L. Gillet, E. Bon, S. Marionneau-Lambot, T. Ouiller, V. Joulin, J.C. Pagès, S. Chevalier, P. Besson, S. Roger (France)
- Improvement of specificity and safety of skin gene electrotransfer for plasmid DNA under the control of tissue-specific promoter** 491
S. Kos, N. Tesic, U. Kamensek, T. Blagus, M. Cemazar, S. Kranjc, J. Lavrencak, G. Sersa (Slovenia)
- Anti-cancer drug discovery based on modulation of alternative splicing** 492
E. Star, L. Li, S. Harper, D. Bates, S. Oltean (United Kingdom)
- Development of dual-targeted inhibitors for the treatment of cancer** 493
J. Hengst, T. Dick, V. Kale, A. Colledge, R. Paulson, J. Yun (USA)
- Cellular ascorbate regulates DNA damage responses and cytotoxicity of bleomycin** 494
A. Zhitkovich, B. Rubis (USA)
- Nanoparticulated docetaxel exerts enhanced anti-cancer efficacy and overcomes existing limitations of commercial products** 495
E. Eunjung Ko, J.C. Jinhyang Choi, J.J. Joohee Jung, H.K.C. Hye-Kyung Chung, J.H.L. Jae Hee Lee, S.Y.J. Seong-Yun Jeong, S.Y.S. Si Yeol Song, E.K.C. Eun Kyung Choi (Korea)
- CD46 is overexpressed in colorectal cancers and mediates enhanced tumor transduction efficacy of Ad5/35 chimeric adenovirus** 496
Y.S. Cho, S.Y. Kwon, H.M. Do, P.K. To, T.W. Kang, Y.E. Joo, C. Jung (Korea)
- De novo expression of integrin alpha v beta 3 in Cal27 cells results in pSrc (Y418) inhibition and resistance to antitumor drugs** 497
N. Stojanovic, A. Brozovic, D. Majhen, M. Herak Bosnar, G. Fritz, M. Osmak, A. Ambriovic-Ristov (Croatia)
- LY294002@PLGA nanodrug overcomes resistance of PI3K inhibitor in lung cancer cells** 498
W.C. Su, Y.S. Lee, T.L. Tsai (Taiwan)
- Hedgehog signaling inhibition potentiates the effectiveness of cytostatic agents in Ewing sarcoma** 499
K.A. Boehme, J. Nitsch, R. Riester, R. Handgretinger, S.B. Schleicher, T. Kluba (Germany)
- Activation of RAS family members confers resistance to ROS1 targeting drugs** 502
M. Cargnelutti, S. Corso, M. Pergolizzi, D.L. Aisner, R. Dziadziuszko, M. Varella-Garcia, P.M. Comoglio, R.C. Doebele, J. Vialard, S. Giordano (Italy)
- Glutathione-dependent antioxidant response is crucially involved in neuroblastoma multi-drug resistance** 503
R. Colla, B. Marengo, C. De Ciucis, A.L. Furfaro, A. Izzotti, D. Fenoglio, U.M. Marinari, M.A. Pronzato, C. Domenicotti (Italy)
- The inhibitory effect of 10-hydroxy-2-decenoic acid (10-HDA) on breast cancer cell proliferation, migration, adhesion and invasion** 504
W. Tanechpongta, M.I.S.S. Pengpanich, D.R. Jariyapongskul, D.R. Srisupabh (Thailand)
- Development of cyclic peptide CXCR4 antagonist—Peptide R derivatives with higher stability and efficacy. Implication for clinical translation** 505
A.M. Trotta, S. Di Maro, C. Ieranò, C. D'Alterio, M. Napolitano, R.A. Siciliano, M.F. Mazzeo, L. Marinelli, E. Novellino, S. Scala (Italy)
- Molecular mechanisms of sensitivity and resistance to the atypical retinoid ST1926 in colon cancer cells** 507
R. Abdel-Samad, Z. Sweidan, R. Hmadi, W. Abou Kheir, M. El-Sabban, H. Muhtasib, C. Pisano, N. Darwiche (Lebanon)
- MicroRNA-21 inhibition enhances chemosensitivity of doxorubicin-resistant glioblastoma cells** 509
L. Giunti, M. Da Ros, A.L. Iorio, S. Becciani, A. Stival, M. Lucchesi, L. Facchini, M. De Martino, L. Genitori, I. Sardi (Italy)
- In vitro cytotoxic activities of the oral platinum(IV) prodrug oxoplatin and HSP90 inhibitor ganetespib against a panel of gastric cancer cell lines** 511
G. Hamilton, B. Rath, L. Klameth (Austria)
- Repurposing valproic acid and simvastatin to enhance the antitumor effect of docetaxel in prostate cancer cells** 512
F. Iannelli, B. Pucci, M.R. Milone, R. Lombardi, A. Budillon, F. Bruzzese (Italy)
- Anti-mitochondrial therapy in pancreatic adenocarcinoma** 513
A. Alistar, R. Desnoyer, A. Cameron, C. Clark, P. Shen, A. Neal, R. Rodriguez (USA)
- Search for therapeutic response molecular markers in malignant melanoma through NGS: On the way to an anti-BRAF combination therapy** 514
M. Pisano, A. Manca, G. Palmieri, M. Casula, A. Cantara, M.A. Dettori, D. Fabbri, C. Rozzo (Italy)

	ABSTRACT NR.		ABSTRACT NR.
Synergistic anti-cancer effect of photodynamically-active hypericin and natural antibiotic Manumycin A on oxaliplatin-resistant colon adenocarcinoma cells <i>M. Macejova, V. Sackova, R. Jendzelovsky, P. Fedorocko (Slovak Republic)</i>	515	JUN mediates melanoma phenotype-switching and confers cell survival during early adaptive resistance to BRAF/MEK inhibitor therapy <i>R. Ramsdale, R.N. Jorissen, F.Z. Li, S. Al-Obaidi, T. Ward, K.E. Sheppard, H. Rizos, G.A. McArthur, A.S. Dhillon, P. Ferrao (Australia)</i>	531
Cannabinoids-based therapies for the treatment of HER2-positive breast cancer <i>S. Blasco-Benito, C. Andradas, E. Pérez-Gómez, M. Guzmán, C. Sánchez (Spain)</i>	516	Inhibition of melanoma metastasis to the lung by fungal metabolites with peroxiredoxin-like peroxidase activity <i>S.W. Kang, D.H. Kang, D.J. Lee (Korea)</i>	532
Nrf2-dependent antioxidant response in cancer cell resistance to bortezomib <i>A. Furfaro, S. Piras, C. Domenicotti, A. De Luigi, M. Salmona, L. Moretta, U.M. Marinari, M.A. Pronzato, N. Traverso, M. Nitti (Italy)</i>	517	Apoptotic effect of caffeic acid phenethyl ester on chromosomally instable <i>bub1Δ</i> and <i>bub3Δ</i> <i>saccharomyces cerevisiae</i> strains <i>S. Yilmaz, Z.N. Akpınar, H. Arikoglu, A. Kiyici, M. Oncel, R. Yilmaz, T. Toka-Ozer, E. Gunduz, M. Gunduz (Turkey)</i>	533
Development of new monoclonal antibodies as target therapy for the treatment of colorectal cancer <i>C. Valvo, R. Morita, M.L. De Angelis, M. Cappellari, E. Petrucci, M.R. Sciuto, M. Mottolose, M. Biffoni, T.L. Hass, R. De Maria (Italy)</i>	518	Molecular and Genetic Epidemiology II	
Fibroblast Growth Factor Receptor (FGFR)3 promotes acquired resistance to trastuzumab in gastric cancer <i>G. Piro, C. Carbone, S. Zanini, F. Di Nicolantonio, F. Boschi, M. Zanotto, M.M. Mina, A. Scarpa, G. Tortora, D. Melisi (Italy)</i>	519	Discovery of new potential genetic biomarkers of epithelial ovarian cancer prognosis <i>K. Elsnerova, B. Mohelnikova-Duchonova, M. Ehrlichova, I. Gut, L. Rob, P. Skapa, A. Bartakova, J. Bouda, P. Soucek, R. Vaclavikova (Czech Republic)</i>	543
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways <i>E. Mini, I. Landini, L. Lucarini, S. Nobili, E. Masini, F. Moroni (Italy)</i>	520	Vimentin is a new molecular partner of LASP-1 in human hepatocellular carcinoma cells <i>A. Salvi, I. Bongarzone, L. Ferrari, E. Abeni, B. Arici, M. De Bortoli, S. Scuri, D. Bonini, I. Grossi, G. De Petro (Italy)</i>	545
PPAR-gamma stimulation in the prophylaxis of 5-FUoro-Uracil induced mucositis <i>M. Loi, M.A. Sottili, C. Gerini, M. Baki, D. Scartoni, F. Castiglione, I. Meattini, I.F. Furfaro, M. Mangoni, L. Livi (Italy)</i>	522	Association between the vitamin D receptor <i>Bsm1</i> polymorphism and breast cancer risk in Pakistan <i>M.U. Rashid, F.A. Khan, M. Muzaffar, N. Muhammad, S. Faiz, M. Kabisch, A. Loya, U. Hamann (Pakistan)</i>	546
Overexpression of ABC family members is associated with intrinsic and acquired gemcitabine resistance in gallbladder cancer cell lines <i>P. García, P. Leal, C. Bizama, J. Espinoza, H. Weber, M.J. Apud, B. Nervi, J.C. Roa (Chile)</i>	523	Prevention and Early Detection II	
Identification of selective inhibitors of the spindle assembly checkpoint kinase TTK (<i>Mps1</i>) for treatment of triple negative breast cancer <i>C.J.R. Zaman, J. De Man, J.C.M. Uitdehaag, A.R.R. Maia, M.B.W. Prinsen, N. Willemsen-Seegers, J. Jonkers, G.J.P.L. Kops, R.H. Medema, R.C. Buijsman (Netherlands)</i>	524	Circulating free DNA: A 'liquid biopsy' for the early detection of cancer? <i>R. Trigg, C. Rakhit, S. Giblett, M. Kelly, J. Janus, L.M. Martins, J.A. Shaw, C.A. Pritchard (United Kingdom)</i>	553
The chromatin remodeler, cohesin subunit SA-1 is a novel sorafenib target against hepatocellular carcinoma <i>M. Delacruz, R. Kalman, B. Latif, R.K. Wali, N. Momi, A. Chhparia, V. Backman, H. Roy (USA)</i>	525	Pirc rat, mutated in <i>Apc</i> , as a tool to study colon cancer and to identify drugs interfering with the early or late events of carcinogenesis <i>A.P. Femia, C. Luceri, G. Caderni (Italy)</i>	555
Genomic drivers of multiple myeloma and consequences for targeted drug response <i>D. Tamborero, M.M. Majumder, R. Silvennoinen, S. Eldfors, J. Lievonen, A. Parsons, M. Suvela, N. Lopez-Bigas, K. Porkka, C. Heckman (Spain)</i>	526	Radiobiology/Radiation Oncology II	
Selective inhibitors targeting indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase <i>C.J.R. Zaman, J.C.M. Uitdehaag, N. Willemsen-Seegers, A.M. Van Doornmalen, J. De Man, R.C. Buijsman (Netherlands)</i>	527	Tumor-macrophage fusion hybrids contribute to tumor radiation resistance via epithelial mesenchymal transition <i>H. Ch'ang, H. Yeh, Y. Chang, Y. Tsai, T. Chang (Taiwan)</i>	563
Dextran-Catechin conjugate: Targeting copper metabolism in neuroblastoma <i>O. Vittorio, M. Brandl, G. Cirillo, K. Kimpton, E. Hinde, H.T.T. Duong, C. Boyer, M. Kavallaris (Australia)</i>	528	Radiosensitization with combined use of olaparib and PI-103 and underlying mechanism in triple-negative breast cancer <i>N. Jang, D. Kim, B. Cho, E. Choi, I.A. Kim (South Korea)</i>	564
Jadomycin B is selectively toxic to triple negative human breast cancer cells in a zebrafish xenotransplantation model <i>S.R. Hall, J. Toulany, C.J. Veinotte, B. Razaghi, A.W. Robertson, C. Martinez-Farina, D.L. Jakeman, G. Dellaire, J.N. Berman, K.B. Goralski (Canada)</i>	529	Early positive detection of tumor radiotherapy effect by mitochondrial complex I activity using a novel PET probe [18] F-BCPP-EF <i>C. Murayama, A.T. Kawaguchi, A. Kamijo, M. Kanazawa, H. Tsukada (Japan)</i>	565
Resistance to a MEK inhibitor, AZD6244: Association with increased Immunoglobulin Transcription Factor-2 through WNT-independent canonical pathway in melanoma cells <i>H. Eun-hye, B.K. Goo, J. Moon, Y. Choi, J. Shin, S.D. Kim, J. Hwang, C.S. Kim, S.H. Yang, J.H. Lee (South Korea)</i>	530	Effect of alpha lipoic acid on radiation-induced small bowel injury in mice model <i>B. Jeong, C.G. Young, H.S. Choi, J.H. Kim, H.J. Jeong, J.H. Jung, J.R. Hahm, K.M. Kang (Korea)</i>	567
		Attenuation of radiation-induced lung damage by a PPAR-gamma agonist <i>M. Mangoni, M. Sottili, C. Gerini, P. Bonomo, A. Bottoncetti, F. Castiglione, S. Pallotta, A. Pupi, E. Vanzi, L. Livi (Italy)</i>	569

Signalling Pathways II

Afatinib inhibits EGFR wild-type NSCLC cells through CIP2A to reactivate protein phosphatase 2A 591
T. Chao, C.Y. Wang, Y.T. Tsai (Taiwan)

Global mapping of tyrosine kinase-regulated signaling dynamics by combined use of SILAC- quantitative proteomics and RNAi screening: The TK-SILACepedia 592
H. Zhang, N. Angelopoulos, Y. Xu, J. Stebbing, G. Giamas (United Kingdom)

TRAIL-based therapeutics in osteosarcoma: Involvement of bone tumor microenvironment in TRAIL resistance 595
R. Guiho, K. Biteau, J. Taurelle, V. Trichet, F. Tirode, D. Heymann, F. Redini (France)

The Organic Cation Transporter OCTN1, genetically linked to inflammatory bowel disease, promotes IL-1beta processing and prevents colon cancer in Apc/Min mice 596
G. Pani, G. Maulucci, D. Samengo, G. Toietta (Italy)

Feedback autocrine loop of FGF-FGFR activates ERK rebound to MEK inhibition in HNSCC 597
Y. Yang, H.J. Na, W.S. Kim, M.J. Ban, J.W. Chang, J.W. Kim, J.H. Park, E.C. Choi, Y.W. Koh (South Korea)

cMET and its ligand stromal HGF secretion induce innate resistance to BRAF inhibitor in BRAF mutant anaplastic thyroid cancer 598
Y. Yang, H.W. Na, H.K. Byeon, W.S. Kim, J.W. Chang, M.J. Ban, J.W. Kim, J.H. Park, E.C. Choi, Y.W. Koh (South Korea)

Phosphoproteomics unravels drug-able signaling networks in gastric cancer 599
Y. Lim, B.Y. So, P.B.O. Tan, K.G. Yeoh (Singapore)

The HSP90 inhibitor, onalespib (AT13387), overcomes acquired resistance to erlotinib and crizotinib in resistance models of NSCLC 601
K. Hearn, T. Smyth, A. Courtin, N. Thompson, J. Lyons, N. Wallis (United Kingdom)

Discovery of a new isoform of BRAF 3'UTR in melanoma 602
A. Marranci, A. Tuccoli, C. Valdes, F. Russo, L. Polisenio (Italy)

Novel small molecule inhibitor effectively inhibits cell viability on wide spectrum of cancer cells 603
L. Kékesi, T. Cheng, A. Sipos, B. Lim, J. Gunaratne, H. Fan, G. Kéri, L. Orfi, D. Lim, B.T. Chua (Singapore)

The reciprocal regulation between TRAP1 and BRAF is responsible for control of cell cycle progression and modulation of mitochondrial apoptotic pathway 605
F. Maddalena, V. Condelli, L. Sisinni, G. Lettini, D.S. Matassa, A. Piscazzi, G. Palladino, M.R. Amoroso, F. Esposito, M. Landriscina (Italy)

Identification of regulatory networks associated with survival of patients suffering from stage I epithelial ovarian cancer 606
E. Calura, L. Paracchini, R. Fruscio, A. Ravaggi, P. Martini, G. Sales, D. Katsaros, M. D'Incalci, S. Marchini, C. Romualdi (Italy)

DJ-1, a PTEN inhibitor, is needed for cancer invasion in many tumor types through the activation of Rho GTPases 607
M. El-Sibai (Lebanon)

Investigating the role of annexin A2 in epidermal growth factor (EGF) induced signalling 609
S. Castaldo, A.T. Tanjeko, N.V. Conchinha, P.A. Madureira (Portugal)

ErbB3 receptor plays a fundamental role in the early and long time response to BRAF/MEK inhibitors in melanoma 610
L. Fattore, D. Malpicci, E. Marra, A. Noto, C. De Vitis, M.E. Pisanu, L. Aurisicchio, P.A. Ascierto, R. Mancini, G. Ciliberto (Italy)

Protein tyrosine phosphatase receptor type gamma increases Jak2 and beta catenin degradation in chronic myeloid leukemia 611
L. Tomasello, M. Vezzalini, G. Silvestri, Z. Fiorini, C. Sorio (Italy)

ERK1/2 phosphorylation and Bcl-xL modulate cell death and drug resistance in edelfosine-treated glioblastoma cells 612
S. Melo-Lima, M. C. Lopes, F. Mollinedo (Portugal)

Translational Research II

Methylation status of histone 3 lysine can predict the prognosis of glioblastoma patients with methylated MGMT gene promoter 665
Y.Z. Kim, K.H. KIM, E.H. LEE (South Korea)

Mechanisms of resistance to venetoclax (ABT-199) and strategies to circumvent it in leukemia and lymphoma cell lines 666
S.K. Tahir, M.L. Smith, P. Hessler, L. Roberts-Rapp, A.J. Souers, D.C. Phillips, J.D. Levenson, L.T. Lam (USA)

FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance 667
G. Nestal de Moraes, D. Delbue, K.L. Silva, M.C. Robaina, P. Khongkow, A.R. Gomes, S. Crocamo, A.L. Mencalha, E.W. Lam, R.C. Maia (Brazil)

Chemically-modified microRNA-205 inhibits the growth of melanoma cells in vitro and its clinical trial in canine melanomas 668
Y. Akao (Japan)

Gain-of-function nature of human ALK (Anaplastic lymphoma kinase) Y1278S mutation found in neuroblastoma favors a new perspective to the ALK activation mechanisms 669
D. Chand, K.R. Ruuth, Y.Y. Yamazaki, J.G. Guan, R.H.P. Ruth H Palmer, B.H. Hallberg (Sweden)

Targeting a novel MYCN mediator, PA2G4, as a therapeutic approach for the treatment of neuroblastoma 670
B.B. Cheung, J.K. Jessica Koach, J.H. Jessica Holien, G.M. Giorgio Milazzo, M.H. Michelle Haber, M.D.N. Murray D. Norris, J.F. Jamie Fletcher, M.P. Michael Parker, G.P. Giovanni Perini, G.M.M. Glenn M. Marshall (Australia)

KITENIN/ErbB4-c-Jun axis confers resistance to cetuximab in colorectal cancer 671
K. Kim, J.A. Bae, J.H. Lee, Y.E. Joo, I.J. Chung, H. Kim (South Korea)

The cytotoxicity of nutraceuticals in both the free and liposomal bound form against K562 cancer cells 672
J. Thornthwaite, H. Shah, S. England, L. Roland, M. Clarke, A. Taylor, C. Faulk (USA)

Expression of tNASP in prostate cancer: Opportunities for a novel diagnostic and prognostic biomarker 673
O. Alekseev, L. Barba, B. Taylor (USA)

Organoid cultures of human colon adenocarcinoma for modelling of drug response 674
H.E. Francies, M. Van de Wetering, J. Francis, G. Bounova, F. Iorio, J. Saez-Rodriguez, L. Wessels, M. Meyerson, H. Clevers, M.J. Garnett (United Kingdom)

Integrin-linked kinase is a key mediator of stromal cell-enhanced resistance of CML stem/progenitor cells to tyrosine kinase inhibitors 676
K. Rothe, A. Watanabe, D. Forrest, S. Dedhar, C. Eaves, X. Jiang (Canada)

The ratio of ErbB4:ErbB3 predicts preclinical activity of the ErbB3-directed therapeutic MM-121 677
L. Nie, M. Sevecka, O. Burenkova, G. MacBeath (USA)

Gene electrotransfer of canine interleukin 12 into canine melanoma cell lines 678
U. Lamprecht, U. Kamensek, M. Stimac, G. Sersa, N. Tozon, M. Bosnjak, A. Brozic, M. Cemazar (Slovenia)

	ABSTRACT NR.		ABSTRACT NR.
Antitumor efficacy of the sequential treatment of Vinorelbine and Gefitinib in Non-Small Cell Lung Cancer cell lines: In vitro and in vivo results <i>M. Dal Bello, A. Alama, S. Coco, I. Vanni, A. Truini, G. Barletta, E. Rijavec, C. Genova, G. Sambuceti, F. Grossi (Italy)</i>	679	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study <i>I. Craparotta, L. Beltrame, R. Fruscio, E. Calura, B. Chapman, L. Clivio, C. Mele, P. Iatropoulos, M. D'Incalci, S. Marchini (Italy)</i>	698
The role of circulating free DNA and circulating tumor cells in advanced non-small cell lung cancer patients <i>A. Truini, C. Genova, A. Alama, S. Coco, M.G. Dal Bello, I. Vanni, E. Rijavec, G. Barletta, F. Biello, F. Grossi (Italy)</i>	680	Multi-modal nanomedicine for glioblastoma <i>P. Ofek, M. Calderon, F. Sheikhi-Mehrabadi, S. Ferber, R. Haag, R. Satchi-Fainaro (Israel)</i>	699
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1 <i>C. Fusi, S. Materazzi, S. Benemei, E. Coppi, G. Trevisan, I.M. Marone, F. De Logu, P. Geppetti, R. Nassini (Italy)</i>	682	Valproic Acid potentiates the anticancer activity of capecitabine in vitro and in vivo breast cancer models by inducing thymidine phosphorylase expression <i>M. Terranova Barberio, M.S. Roca, A. Leone, F. Bruzzese, A. Budillon, E. Di Gennaro (Italy)</i>	700
Dogs with naturally occurring cancers as new predictive models for human pathology: A fast and relevant way to optimize clinical development <i>Z. Segoula, I. Bemelmans, E. Bouchaert, P. Ostyn, Y. Touil, R. Polakowska, P. Formstecher, B. Quesnel, D. Tierny, X. Thuru (France)</i>	683	Derivation and characterization of cancer-initiating cells representative of metastatic colorectal cancer genetic heterogeneity <i>V. Bigatto, P. Luraghi, E. Cipriano, G. Reato, F.N. Orzan, R. Neggia, A. Bertotti, L. Trusolino, P.M. Comoglio, C. Boccaccio (Italy)</i>	701
Red pigment from saw palmetto: A natural product for potential alternative cancer treatment <i>Y. Feng, S. Okuda, H.Y. Tan, N. Wang, S.W. Tsao, M. Takahashi, (Hong Kong)</i>	684	Choline metabolism is an early predictor of EGFR-mediated survival in NSCLC <i>R. Favicchio, D. Brickute, N. Angelopoulos, R. Fortt, F. Twyman, G. Giamas, J.C. Lacal, E.O. Aboagye (United Kingdom)</i>	702
Ondansetron modulates the multidrug resistance phenotype in preclinical model of brain tumors <i>A. Iorio, M. Da Ros, O. Fantappiè, L. Giunti, S. Becciani, A. Stival, M. Lucchesi, L. Facchini, R. Mazzanti, I. Sardi (Italy)</i>	685	Clinical significance of Anoctamin-1 gene at 11q13 in laryngeal tumorigenesis <i>E.J. Hermida-Prado, S.T. Menéndez, J.P. Rodrigo, S. Alvarez-Teijeiro, M.A. Villaronga, L. Alonso-Durán, M. Araujo-Voces, A. Astudillo, C. Suárez, J.M. García-Pedrero (Spain)</i>	703
Value of the prognostic biomarkers related to TP53 pathway after >10 years in a cohort of 61 locally advanced head and neck cancers <i>C. Lo Nigro, M. Monteverde, D. Vivenza, N. Denaro, A. Comino, E. Russi, M. Merlano (Italy)</i>	686	The role of nitric oxide in generation and maintenance of cancer stem cells: New therapeutic opportunities in cancer <i>J. Peñarando, L.M. López-Sánchez, A. Cañas, A. Valverde, V. Hernández, C. López-Pedreña, J.R. De la Haba-Rodríguez, E. Aranda, A. Rodríguez-Ariza (Spain)</i>	704
In vivo efficacy evaluation of doxorubicin on tumor regression on a xenograft mice model pre-treated with morphine <i>M. Da Ros, A.L. Iorio, M.L. Della Bona, S. Becciani, A. Stival, M. Lucchesi, L. Facchini, G. La Marca, M. De Martino, I. Sardi (Italy)</i>	687	Targeting CXCR4 with new cyclic peptide antagonists potentiates conventional chemotherapy in in vivo colorectal cancer <i>C. D'Alterio, A. Zannetti, M. Napolitano, G. Botti, A. Greco, P. Maiolino, S. Albanese, F. Tatangelo, A. Avallone, S. Scala (Italy)</i>	705
Hereditary genetic polymorphisms of suppressor of cytokine signaling 5 (SOCS5) gene predicts prognosis of patients with esophageal squamous cell carcinoma <i>L. Wong, P. Yang, T. Chiang, M. Hsieh, J. Lee (Taiwan)</i>	688	Novel insight into Notum and glypicans regulation in a colorectal cancer mouse model <i>M. De Robertis, M. Arigoni, L. Loiacono, F. Riccardo, R.A. Calogero, F. Cavallo, V.M. Fazio, E. Signori (Italy)</i>	706
Radiolabeled click-chemistry derived non-peptide RGD peptidomimetics for SPECT molecular imaging of melanoma <i>F. Bianchini, S. Peppicelli, G. Menchi, S. Raspanti, A. Bottoncetti, A. Passeri, A. Guarna, L. Calorini, A. Trabocchi, A. Pupi (Italy)</i>	689	Phenethyl isothiocyanate hampers tumor growth and progression of d16HER2-positive breast cancer <i>A. Koschorke, L. Castagnoli, G.C. Ghedini, L. Galvani, A. Lamolinara, M. Iezzi, R. Canese, P. Nanni, E. Tagliabue, S.M. Pupa (Italy)</i>	707
Chemical genetics uncovers a vulnerability of breast cancer cells harbouring a highly frequent GATA3 mutation <i>B. Mair, M.K. Mueller, C. Kerzendorfer, K. Sleiman, S. Kubicek, S.M.B. Nijman (United Kingdom)</i>	690	Photo-acoustic and sonoporation methods: Synergic improvement in tumoral treatment <i>P. Giustetto (Italy)</i>	708
Assessing the biological role of miR-211 family in a zebrafish melanoma model <i>S. Sarti, E. Guzzolino, L. Mariani, Y. Houvras, L. Pitto, L. Polisenio (Italy)</i>	693	Development of small molecule activators of protein phosphatase 2A (SMAPs) for the treatment of high-grade serous ovarian and uterine cancer <i>S.S. Singh, A.A. Armstrong, P.J. Joseph, K.R. Resnick, K.Z. Zanotti, S.W. Waggoner, M.O. Ohlmeyer, G.N. Narla, A. DiFeo (USA)</i>	709
Tracking in vivo CXCR4 expressing human cancer cells with a near infrared labelled-CXCR4 cyclic peptide antagonist Peptide R <i>S. Santagata, A. Zannetti, C. D'Alterio, M. Napolitano, L. Portella, M.V. Barone, A. Barbieri, A. Luciano, C. Arra, S. Scala (Italy)</i>	695	Novel therapeutic approaches for human malignant mesothelioma <i>H. Yang, M. Carbone (USA)</i>	710
Targeting Aurora kinases and cyclin-dependent kinase 2 (CDK2) in osteosarcoma <i>S. Vella, E. Tavanti, M. Fanelli, C.M. Hattinger, R. Versteeg, P. Picci, M. Serra (Italy)</i>	696	Validation of drug resistant murine tumor models to facilitate development of new anticancer therapeutics <i>Y. Jin, J. Zhang, D. Zhu, Y. Sun, G. Mao, M. Wang, Q. Shi (USA)</i>	711
Changes in linc-RNA expression associated with the outcome of stage I epithelial ovarian cancer <i>L. Paracchini, P. Martini, S. Cagnin, L. Beltrame, R. Fruscio, A. Ravaggi, E. Bignotti, M. Mello Grand, M. D'Incalci, C. Romualdi (Italy)</i>	697	Overcoming primary and acquired resistance to ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells: Rationale to combine metformin <i>J. Kim, M.Y. Kim, G.O. Kim, T.M. Kim (Korea)</i>	712

	ABSTRACT NR.		ABSTRACT NR.
The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth	713	Tumour Immunology II	
V. Grantcharova, <u>K. Masson</u> , O. Burenkova, M. Wainszelbaum, S. Iadevaia, S. Adams, A. Raue, A. Czibere, B. Schoeberl, G. MacBeath (USA)		Novel immunotherapeutic regimen consisting of adoptive T-cell transfer and cytokine-coding adenoviruses for the treatment of melanoma	731
ETV4 overexpression cooperates with Pten deletion for prostate cancer progression in mice	714	<u>M. Siurala</u> , R. Havunen, S. Bramante, D. Saha, S. Tähtinen, M. Vähä-Koskela, A. Hemminki (Finland)	
E. De Lorenzo, A. Pellecchia, I. Cosi, C. Pescucci, E. Torre, M. Sica, G. Nesi, R. Notaro, <u>M. De Angioletti</u> (Italy)		How adenosinergic pathways in the myeloma niche are instrumental in reorganizing normal bone to favor tolerogenesis and local growth	732
The Spindle Assembly Checkpoint (SAC) is required for the activity of the novel anti-cancer agent BAL101553 (prodrug of BAL27862)	715	<u>A. Horenstein</u> , A. Chillemi, V. Quarona, V. Ferri, M. Bolzoni, F. Morandi, V. Pistoia, N. Giuliani, F. Malavasi (Italy)	
<u>H.A. Lane</u> , K. Burger, F. Bachmann (Switzerland)		Anti-cancer drug Combretastatin (CA)-4 and its novel analogue CA-432 display anti-inflammatory properties in T-cells	733
Oncogenic TBX2 confers cisplatin resistance in breast cancer and melanoma by promoting DNA repair	716	<u>J. Pollock</u> , N. Verma, N. O'Boyle, M. Carr, M. Meegan, D. Zisterer (Ireland)	
S. Wansleben, E. Davis, J. Peres, <u>S. Prince</u> (South Africa)		C3a complement activation and blood coagulation drive a protumorigenic phenotype in neutrophils and promote intestinal tumorigenesis	736
		<u>S. Guglietta</u> , A. Chiavelli, E. Zagato, C. Krieg, S. Gandini, P.S. Ravenda, B. Lu, G. Penna, M. Rescigno (Italy)	
		PD-1+ T cells mediate early phases of anti-tumor immunity in NSCLC	
		E. Tassi, C. Vegetti, A. Molla, P. Baldassari, L. Roz, G. Sozzi, U. Pastorino, <u>R. Mortarini</u> , A. Anichini (Italy)	